<article xmlns="http://dtd.nlm.nih.gov/2.0/xsd/archivearticle" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://dtd.nlm.nih.gov/2.0/xsd/archivearticle http://dtd.nlm.nih.gov/2.0/xsd/archivearticle.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Chem Phys Lipids</journal-id>
      <journal-title-group>
        <journal-title>Chemistry and Physics of Lipids</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0009-3084</issn>
      <issn pub-type="epub">1873-2941</issn>
      <publisher>
        <publisher-name>Elsevier Science Ireland Ltd</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmc">3220766</article-id>
      <article-id pub-id-type="pmid">21945565</article-id>
      <article-id pub-id-type="publisher-id">CPL4056</article-id>
      <article-id pub-id-type="doi">10.1016/j.chemphyslip.2011.09.004</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Membrane-active host defense peptides – Challenges and perspectives for the development of novel anticancer drugs</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Riedl</surname>
            <given-names>Sabrina</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zweytick</surname>
            <given-names>Dagmar</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lohner</surname>
            <given-names>Karl</given-names>
          </name>
          <email>karl.lohner@oeaw.ac.at</email>
          <xref rid="cor0005" ref-type="corresp">⁎</xref>
        </contrib>
      </contrib-group>
      <aff>Institute of Biophysics and Nanosystems Research, Austrian Academy of Sciences, Schmiedlstraße 6, A-8042 Graz, Austria</aff>
      <author-notes>
        <corresp id="cor0005"><label>⁎</label>Corresponding author. Tel.: +43 316 4120 323; fax: +43 316 4120 390. <email>karl.lohner@oeaw.ac.at</email></corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
        <month>11</month>
        <year>2011</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="ppub"/>. -->
      <pub-date pub-type="ppub">
        <month>11</month>
        <year>2011</year>
      </pub-date>
      <volume>164</volume>
      <issue>8</issue>
      <fpage>766</fpage>
      <lpage>781</lpage>
      <history>
        <date date-type="received">
          <day>20</day>
          <month>6</month>
          <year>2011</year>
        </date>
        <date date-type="rev-recd">
          <day>7</day>
          <month>9</month>
          <year>2011</year>
        </date>
        <date date-type="accepted">
          <day>8</day>
          <month>9</month>
          <year>2011</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© 2011 Elsevier Ireland Ltd.</copyright-statement>
        <copyright-year>2011</copyright-year>
        <copyright-holder>Elsevier Ireland Ltd</copyright-holder>
        <license>
          <license-p>This document may be redistributed and reused, subject to <ext-link ext-link-type="uri" xlink:href="http://www.elsevier.com/wps/find/authorsview.authors/supplementalterms1.0">certain conditions</ext-link>.</license-p>
        </license>
      </permissions>
      <abstract abstract-type="graphical">
        <title>Highlights</title>
        <p>► Outlined the need of novel strategies for cancer therapies that can counteract problems arising particularly in chemotherapy due to resistance to current drugs and their low specificity. ► Elaborated the differences in membrane composition and properties between cancer and non-cancer cells, the basis for the use of anticancer peptides derived from host defense peptides as new weapons against cancer. ► Described the current knowledge on the mode of action of these peptides and the status of <italic>in vivo</italic> studies. ► Summarized the challenges and perspectives for the development of host defense peptides as novel anticancer agents.</p>
      </abstract>
      <abstract>
        <p>Although much progress has been achieved in the development of cancer therapies in recent decades, problems continue to arise particularly with respect to chemotherapy due to resistance to and low specificity of currently available drugs. Host defense peptides as effector molecules of innate immunity represent a novel strategy for the development of alternative anticancer drug molecules. These cationic amphipathic peptides are able to discriminate between neoplastic and non-neoplastic cells interacting specifically with negatively charged membrane components such as phosphatidylserine (PS), sialic acid or heparan sulfate, which differ between cancer and non-cancer cells. Furthermore, an increased number of microvilli has been found on cancer cells leading to an increase in cell surface area, which may in turn enhance their susceptibility to anticancer peptides. Thus, part of this review will be devoted to the differences in membrane composition of non-cancer and cancer cells with a focus on the exposure of PS on the outer membrane. Normally, surface exposed PS triggers apoptosis, which can however be circumvented by cancer cells by various means.</p>
        <p>Host defense peptides, which selectively target differences between cancer and non-cancer cell membranes, have excellent tumor tissue penetration and can thus reach the site of both primary tumor and distant metastasis. Since these molecules kill their target cells rapidly and mainly by perturbing the integrity of the plasma membrane, resistance is less likely to occur. Hence, a chapter will also describe studies related to the molecular mechanisms of membrane damage as well as alternative non-membrane related mechanisms. <italic>In vivo</italic> studies have demonstrated that host defense peptides display anticancer activity against a number of cancers such as e.g. leukemia, prostate, ascite and ovarian tumors, yet so far none of these peptides has made it on the market. Nevertheless, optimization of host defense peptides using various strategies to enhance further selectivity and serum stability is expected to yield novel anticancer drugs with improved properties in respect of cancer cell toxicity as well as reduced development of drug resistance.</p>
      </abstract>
      <kwd-group>
        <title>Abbreviations</title>
        <kwd>PS, phosphatidylserine</kwd>
        <kwd>bLFcin, bovine lactoferricin</kwd>
        <kwd>pHLIP, pH (low) insertion peptide</kwd>
      </kwd-group>
      <kwd-group>
        <title>Keywords</title>
        <kwd>Anticancer peptides</kwd>
        <kwd>Cancer cell membrane</kwd>
        <kwd>Cancer selective toxicity</kwd>
        <kwd>Targeted cancer therapy</kwd>
        <kwd>Membrane permeabilization</kwd>
        <kwd>Phosphatidylserine exposure</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec id="sec0005">
      <label>1</label>
      <title>Introduction</title>
      <p>Cancer is a leading cause of death worldwide representing about one-eighth of all deaths (<ext-link ext-link-type="uri" xlink:href="http://www.who.int/mediacentre/factsheets/fs297/en/">http://www.who.int/mediacentre/factsheets/fs297/en/</ext-link>) and being strongly affected by demographic changes especially ageing of the population. In 2008, more than 12.7 million people were newly diagnosed with cancer accounting for 7.6 million deaths, with over one quarter of the global cancer incidences occurring in Europe. Furthermore, cancer has also emerged as a major public health problem in developing countries. According to the World Health Organization new cases of cancer impairment will strongly increase with estimated death rates of up to 11 million in the year 2030. Although in recent decades much progress has been achieved in respect of therapies, like surgery, chemotherapy, radiation or hormone ablation therapy, they are not successful in more than 50% of cases (<ext-link ext-link-type="uri" xlink:href="http://globocan.iarc.fr/factsheets/populations/factsheet.asp%3Funo=900">http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900</ext-link>). Furthermore, for those who survive the risk of reoccurrence of the disease is a major problem. If the tumor progresses or reoccurs, chemotherapy is the standard treatment. However, resistance as well as potential toxicity and the many side effects of chemotherapeutics, which are mainly due to inadequate specificity for tumor cells, represent a major limitation in this type of therapy. Hence, increasingly the identification of more specific targets generally expressed within a certain tumor type is a major issue in anticancer research. While considerable attention is paid to receptors of growth factors and proteins involved in cell–cell signaling relatively little effort has been devoted to targeting cancer cell membranes <italic>per se</italic>. Thus, this review will focus on a promising new approach in cancer therapy which is based on host defense peptides – effector molecules of innate immunity that specifically target cancer cells and destroy them within minutes, mostly by damaging cell membrane without binding to specific receptors.</p>
    </sec>
    <sec id="sec0010">
      <label>2</label>
      <title>Deficits and drawbacks of conventional cancer therapies – need for novel treatment strategies</title>
      <p>Before development of chemotherapeutics in the 1940s (<xref rid="bib0730" ref-type="bibr">Shewach and Kuchta, 2009</xref>), surgical removal of tumor tissue was the only available treatment and can still often be successfully applied for localized cancers for which radiation therapy is also widely used to target cells by directly damaging DNA (<xref rid="bib0805" ref-type="bibr">Tofilon and Camphausen, 2009</xref>). Nevertheless, many cancer types advance rapidly, reoccur or tend to metastasize making chemotherapy the treatment of choice (<xref rid="bib0220" ref-type="bibr">Espinosa et al., 2003</xref>). Currently used anticancer drugs are mostly based on alkylating agents, antimetabolites as well as natural products and derivatives thereof. Between 1940 and 2006, 175 new anticancer drugs were approved (<xref rid="bib0525" ref-type="bibr">Newman and Cragg, 2007</xref>). More than 50% thereof are biological (10% are usually large peptides and proteins), natural (14%) or naturally derived products (28% are semisynthetic modifications) (<xref rid="fig0005" ref-type="fig">Fig. 1</xref>). Early compounds were based on nitrogen mustards, a powerful class of agents that alkylate bases of DNA (<xref rid="bib0735" ref-type="bibr">Shore, 1947</xref>), leading to cell death. A second class of chemotherapeutics, the antimetabolites, such as aminopterin and amethopterin, do not directly interact with DNA bases but interfere with synthesis of precursors as folate and cause mistakes during DNA replication of cancer cells (<xref rid="bib0730" ref-type="bibr">Shewach and Kuchta, 2009</xref>). In the 1960s, natural-product anticancer drugs started to be developed such as e.g. Vinca alkaloids that inhibit microtubule polymerization and thereby cell division or antracyclines that promote cell death upon intercalation in DNA and inhibition of replication (<xref rid="bib0100 bib0075" ref-type="bibr">Chaires, 1985; Capranico et al., 1990</xref>). In the decades that followed a large number of further chemotherapeutics such as taxol or halychondrines and E7389 were developed that interfere with a variety of biological targets (<xref rid="bib0325" ref-type="bibr">Jackson et al., 2009</xref>).</p>
      <sec id="sec0015">
        <label>2.1</label>
        <title>Side effects owing to insufficient selectivity</title>
        <p>Most conventional chemotherapeutics, however, exhibit insufficient selectivity against healthy mammalian cells causing deleterious side effects (<xref rid="bib0750 bib0085 bib0340" ref-type="bibr">Smith et al., 2000; Cassidy and Misset, 2002; Kalyanaraman et al., 2002</xref>). Commonly, these agents act on cells that divide rapidly, one of the main properties of cancer cells. Therefore, damage can be expected in particular in rapidly dividing normal cells, like bone marrow, gastrointestinal mucosa and hair follicles, resulting in the most common side effects of chemotherapy like myelosuppression (decreased production of blood cells), mucositis (inflammation of the lining of the digestive tract) and alopecia (hair loss). Newer chemotherapies, such as the use of monoclonal antibodies (<xref rid="bib0500" ref-type="bibr">Nabholtz and Slamon, 2001</xref>), immunotoxins (<xref rid="bib0575" ref-type="bibr">Pastan and Kreitman, 1998</xref>) or angiogenesis inhibitors (<xref rid="bib0480" ref-type="bibr">Miller et al., 2009</xref>), target specific differences between tumors and healthy cells and tissues, thereby exhibiting lower toxicity. However, side effects have also been observed.</p>
      </sec>
      <sec id="sec0020">
        <label>2.2</label>
        <title>Formation of resistance</title>
        <p>Besides toxicity, resistance to treatment with anticancer drugs is a huge problem. Resistance can be intrinsic and can result from individual variations in patients and somatic cell genetic differences in tumors (<xref rid="bib0255" ref-type="bibr">Gottesman, 2002</xref>). Furthermore, acquired resistance has become common, by e.g. expression of one or more energy-dependent transporters that detect and eject anticancer drugs from cells before interaction with intracellular targets can occur, or acquired insensitivity to drug induced apoptosis and induction of drug-detoxifying mechanism (<xref rid="bib0255 bib0250 bib0585" ref-type="bibr">Gottesman, 2002; Gillet and Gottesman, 2010; Perez-Tomas, 2006</xref>). Hence, many cancer types e.g. malignant melanoma (<xref rid="bib0675 bib0280" ref-type="bibr">Schadendorf et al., 1994; Helmbach et al., 2001</xref>) show only slight sensitivity to anticancer drugs. Treatment with methylating antitumor agent dacarbazine and its oral equivalent temozolomide exhibits a response of only 15% (<xref rid="bib0120 bib0475" ref-type="bibr">Chapman et al., 1999; Middleton et al., 2000</xref>). In metastatic melanoma, resistance is reported to be linked to defective apoptosis due to inhibition of expression of a gene encoding Apaf-1, the apoptotic protease activating factor-1 (<xref rid="bib0760" ref-type="bibr">Soengas et al., 2001</xref>). A number of multidrug-resistant cancers have been detected and thus various approaches including the development of drugs that engage, evade or exploit efflux by ABC transporters have been described (<xref rid="bib0785" ref-type="bibr">Szakacs et al., 2006</xref>).</p>
        <p>Despite all the progress in the design of cancer therapy there is still no cancer treatment that is 100% effective against disseminated cancer (<xref rid="bib0255" ref-type="bibr">Gottesman, 2002</xref>). By contrast, the overall contribution of curative and adjuvant cytotoxic chemotherapy to 5-year survival in adults was estimated to be only 2.3% in Australia and 2.1% in the USA (<xref rid="bib0495" ref-type="bibr">Morgan et al., 2004</xref>). Therefore, the development of new anticancer drugs based on novel mode of actions with improved cancer cell selectivity is urgently needed. Furthermore, patients suffering from cancer with poor treatability like glioblastoma, a cancer of the brain, do not survive longer than 1–2 years even if the cancer is detected early and treated with surgery, chemotherapy, and radiotherapy, (<xref rid="bib0095" ref-type="bibr">CBTRUS, 2008</xref>). Stomach, ovarian and other cancers also demand new effective treatment.</p>
      </sec>
    </sec>
    <sec id="sec0025">
      <label>3</label>
      <title>Host defense peptides selectively targeting differences between cancer and non-cancer cell membranes</title>
      <p>In the search for novel anticancer agents, host defense peptides have emerged as potential alternative anticancer therapeutics offering many advantages over other therapies. Because of their mode of action and specificity – the cell membrane being the major target – resistance and cytotoxicity are less likely to occur (<xref rid="bib0295 bib0560 bib0420 bib0690" ref-type="bibr">Hoskin and Ramamoorthy, 2008; Papo and Shai, 2005; Mader and Hoskin, 2006; Schweizer, 2009</xref>) and thus, they are also expected to cause fewer side effects. Furthermore, these peptides mostly damage cell membranes within minutes (<xref rid="bib0150" ref-type="bibr">Cruciani et al., 1991</xref>), which would hinder formation of resistance (<xref rid="bib0560" ref-type="bibr">Papo and Shai, 2005</xref>). Host defense peptides being part of the innate immune system of many diverse species (e.g. mammals, insects, amphibians) were initially discovered because of their antimicrobial activity (<xref rid="bib0915" ref-type="bibr">Zasloff, 2002</xref>). Currently, the antimicrobial peptide database lists more than 100 natural host defense peptides with antitumor activity (<xref rid="bib0850 bib0840" ref-type="bibr">Wang and Wang, 2004; Wang et al., 2009b</xref>). Selected host defense peptides for which <italic>in vitro</italic> studies were reported are listed in <xref rid="tbl0005" ref-type="table">Table 1</xref>. The most intensively studied antimicrobial peptides that also exhibit cytotoxic activity against cancer cells were described in detail in terms of structure, mode of action and anticancer activity in a recent review by <xref rid="bib0295" ref-type="bibr">Hoskin and Ramamoorthy (2008)</xref>. These host defense peptides are characterized by low molecular weight (in the majority of cases less than 30 amino acids) as well as low antigenicity (<xref rid="bib0320" ref-type="bibr">Iwasaki et al., 2009</xref>) and exhibit a predominantly cationic amphipathic structure making them prone to interact with anionic cell membrane surfaces (<xref rid="bib0400 bib0395" ref-type="bibr">Lohner and Blondelle, 2005; Lohner, 2009</xref>). Indeed, various anionic molecules, discussed in the following, are more abundant on the surface of cancer cells as compared to non-cancer cells. This increased level of negative charge seemingly accounts for the selectivity of these membrane-active peptides towards cancer cells. In addition, one can envisage that anticancer peptides, which translocate to the cytosol, interact preferentially with the mitochondrial membrane owing to its high content of negatively charged lipids such as cardiolipin. As a consequence, the peptides may trigger apoptosis. Of note, mitochondrial membranes of different melanoma variants were shown to also contain significant amounts of phosphatidylserine (<xref rid="bib0685" ref-type="bibr">Schroeder and Gardiner, 1984</xref>). Furthermore, the susceptibility of cancer and non-cancer cells towards anticancer peptides is governed by differences in their membrane fluidity and/or by morphological changes such as the increased number of microvilli found on cancer cells. <xref rid="fig0010" ref-type="fig">Fig. 2</xref> outlines these and additional parameters such as acidification of cancer cell environment that may be of benefit in the anticancer activity of histidin-rich peptides as well as some important processes that suppress apoptosis in cancer cells.</p>
      <sec id="sec0030">
        <label>3.1</label>
        <title>Anionic phosphatidylserine exposed on the outer membrane leaflet of cancer cells</title>
        <p>Indeed, one of the major differences between cancer and non-cancer cell-surfaces is the exposure of the negatively charged lipid phosphatidylserine (PS) on the outer leaflet of the cancer cell membrane, which in non-cancer cells exhibits an overall neutral charge due to the zwitterionic phosphatidylcholine and sphingomyelin (<xref rid="bib0055" ref-type="bibr">Bevers et al., 1996</xref>). Phosphatidylserine together with the major part of phosphatidylethanolamine is normally located in the inner leaflet of eukaryotic plasma membranes (<xref rid="bib0055" ref-type="bibr">Bevers et al., 1996</xref>). This asymmetric distribution of the major phospholipids between the two membrane leaflets is well documented (<xref rid="bib0930 bib0050" ref-type="bibr">Zwaal and Schroit, 1997; Bevers et al., 1998</xref>) and assumed to be maintained by ATP-dependent aminophospholipid translocase activity (<xref rid="bib0695" ref-type="bibr">Seigneuret and Devaux, 1984</xref>) and/or abolished by a Ca<sup>2+</sup>-dependent scramblase activity, which triggers non-specific movement of phospholipids to both leaflets (<xref rid="bib0930" ref-type="bibr">Zwaal and Schroit, 1997</xref>). The loss of membrane asymmetry was demonstrated for several cancer types, revealing a promising uniform marker for cancer. Within some studies, PS exposed on the surface could even be visualized <italic>in vitro</italic> and <italic>in vivo</italic> by specific interaction with Annexin A5 and linked to a fluorophore (<xref rid="bib0170 bib0780 bib0645" ref-type="bibr">Dobrzynska et al., 2007; Szachowicz-Petelska et al., 2002; Riedl et al., 2011b</xref>). Since the pioneering work of <xref rid="bib0815" ref-type="bibr">Utsugi et al. (1991)</xref> showing that tumourigenic cells expose 3–7-fold more PS than normal keratinocytes, PS exposure has been described for human ovarian carcinoma (<xref rid="bib0615" ref-type="bibr">Rao et al., 1992</xref>), human gastric carcinoma (<xref rid="bib0885" ref-type="bibr">Woehlecke et al., 2003</xref>), different melanomas (<xref rid="bib0350 bib0140" ref-type="bibr">Kirszberg et al., 2009; Cichorek et al., 2000</xref>) and leukemias (<xref rid="bib0145 bib0680" ref-type="bibr">Connor et al., 1989; Schröder-Borm et al., 2005</xref>). In an extension of these studies, our laboratory focused on cancer with poor outcome and treatment efficacy including metastases as well as primary cell cultures and demonstrated that differently tumorigenic melanoma cell lines expose 4–11 times more PS than melanocytes (<xref rid="fig0015" ref-type="fig">Fig. 3</xref>), whereby the amount of exposed PS correlated with tumor progression (<xref rid="bib0940 bib0640" ref-type="bibr">Zweytick et al., 2011a; Riedl et al., 2011a</xref>). Furthermore, we proved that not only do cell lines derived from primary lesions and metastasis show PS on the outer leaflet of the cell membrane but also cells from primary cancer cell cultures. The number of different cancer types used in our study including (malignant) melanoma, a rhabdomyosarcoma, a malignant soft tissue tumor of mesenchymal origin, prostate cancer, renal cell cancer and a glioblastoma extended and strongly supported earlier findings, suggesting that PS exposure is a general phenomenon of cancer cells. In general, cells expressing PS in the outer leaflet of the plasma membrane are specifically recognized by the presence of macrophages (<xref rid="bib0235 bib0445" ref-type="bibr">Fadok et al., 1992; Martin et al., 1995</xref>) and dendritic cells (<xref rid="bib0005" ref-type="bibr">Albert et al., 1998</xref>) triggering apoptosis. However tumor cells, although exposing PS, circumvent apoptosis and prevent recognition by macrophages (<xref rid="fig0010" ref-type="fig">Fig. 2</xref>). For example, lung and colon cancer cells secrete elevated levels of a molecule that binds to FasL, a death activator on T-cells, and prevents them being killed. While melanoma inhibit expression of a gene encoding Apaf-1, the apoptotic protease activating factor-1, certain B-cell leukemias and lymphomas express high levels of Bcl-2, a protein that blocks apoptotic signals (<xref rid="bib0760 bib0485" ref-type="bibr">Soengas et al., 2001; Miyashita and Reed, 1993</xref>). Therefore, cationic host defense peptides, which show an excellent tumor tissue penetration reaching the site of both primary tumor and distant metastasis (<xref rid="bib0705" ref-type="bibr">Shadidi and Sioud, 2003</xref>) and specifically interact with anionic membrane lipids (<xref rid="bib0935 bib0950 bib0405" ref-type="bibr">Zweytick et al., 2006, 2011b; Lohner et al., 1997</xref>), represent a promising approach in the development of novel anticancer drugs (<xref rid="bib0295 bib0560 bib0420 bib0690" ref-type="bibr">Hoskin and Ramamoorthy, 2008; Papo and Shai, 2005; Mader and Hoskin, 2006; Schweizer, 2009</xref>). It is also of interest to note that anionic phospholipids are also present on the surface of tumor blood vessels connected to tumor tissue (<xref rid="bib0610" ref-type="bibr">Ran et al., 2002</xref>). The observation of negatively charged tumor vasculature provides an additional potential target for anticancer peptides, which may be also used for imaging. For example, selective staining of vascular endothelium of different tumors and also tumor cells in and around regions of necrosis was shown using 9D2, a monoclonal antibody for anionic phospholipids or Annexin A5 (<xref rid="bib0610" ref-type="bibr">Ran et al., 2002</xref>). Furthermore, it is reported that radio-labeled Annexin A5 may allow for repeated and selective <italic>in vivo</italic> identification of apoptotic cell death without the need for invasive biopsy (<xref rid="bib0825" ref-type="bibr">Van de et al., 2003</xref>), which should also be applicable in the imaging of tumor tissue.</p>
      </sec>
      <sec id="sec0035">
        <label>3.2</label>
        <title>Enhancement of sialic acid residues on cancer cell surface</title>
        <p>Another source of negative charges on the surface of human cells is represented by sialic acid residues, which are linked to glycoproteins (e.g. mucins) and glycolipids. An overexpression of transmembrane mucins was shown e.g. for carcinoma cells from epithelia (<xref rid="bib0365 bib0080" ref-type="bibr">Kufe, 2009; Carraway et al., 1999</xref>) and transmembrane mucin 1 (MUC1) was overexpressed in more than 90% of breast carcinomas and frequently in others such as ovarian, lung, colon and pancreatic carcinoma (<xref rid="bib0030" ref-type="bibr">Bafna et al., 2010</xref>). The extent of surface sialylation seems to be directly correlated with the metastatic potential of different cancer cells exhibiting a protective function against the host immune system and facilitating migration and invasion via modulation of adhesiveness (<xref rid="bib0835 bib0385 bib0090" ref-type="bibr">Wang et al., 2009a; Litynska et al., 2001; Cazet et al., 2010</xref>). The effect of different degrees of sialylation in terms of peptide interaction has been studied less intensively. For example, BMAP-27 and BMAP-28, host defense peptides from the cathelicidin family, exhibited lower activity on cancer cells when sialic acid had been cleaved off (<xref rid="bib0650" ref-type="bibr">Risso et al., 1998</xref>) suggesting that the outside charge seems to act as an initial interaction site for the peptides. By contrast, in a preliminary study performed in our laboratory the activity of peptides derived from a fragment of human lactoferricin, was unaffected by cleavage of sialic acid moieties of a rhabdomyosarcoma (unpublished data), suggesting something other than sialic acid as a preferred target for this tumor type. Summarizing, it is obvious that glycosylation plays an important role in the interaction with peptides. For more details about changes in the glycosylation pattern in cancer cells and impact on cell processes like cancer progression and impairment of signaling pathways see <xref rid="bib0295" ref-type="bibr">Hoskin and Ramamoorthy (2008)</xref>.</p>
      </sec>
      <sec id="sec0040">
        <label>3.3</label>
        <title>Heparan sulfate</title>
        <p>In addition to the above mentioned sources of negative charges on the surface of cancer cells, the role played by proteoglycans should also be noted (<xref rid="bib0355" ref-type="bibr">Kjellen and Lindahl, 1991</xref>). These proteins contain highly negatively charged glycosaminoglycan side chains mainly in the form of heparan sulfate and chondroitin sulfate composed of linear repeats of sulfated disaccharides (<xref rid="bib0775 bib0800" ref-type="bibr">Sugahara et al., 2003; Tkachenko et al., 2005</xref>). These disaccharides contain a high number of sulfate groups yielding highly negatively charged molecules (<xref rid="bib0605" ref-type="bibr">Rabenstein, 2002</xref>). It has been reported for several cancer cells that proteoglycan expression and sulfation is altered (<xref rid="bib0330 bib0360 bib0665 bib0450 bib0670 bib0025 bib0510" ref-type="bibr">Jayson et al., 1998; Kleeff et al., 1998; Safaiyan et al., 1998; Matsuda et al., 2001; Sanderson, 2001; Aviel-Ronen et al., 2008; Nakatsura et al., 2004</xref>). <xref rid="bib0225" ref-type="bibr">Fadnes et al. (2009)</xref> reported that chondoitrin sulfate had no effect on the activity of bovine lactoferricin (bLFcin), which however was improved after depletion of heparan sulfate on cancer cells and lowered upon addition of exogenous heparan sulfate. Although this observation seemingly implies that heparan sulfate may inhibit the activity of anticancer peptides, the same group showed recently that small lytic peptides derived from bLFcin are not affected by heparan sulfate or even possess increased activity in their presence (<xref rid="bib0230" ref-type="bibr">Fadnes et al., 2011</xref>).</p>
      </sec>
      <sec id="sec0045">
        <label>3.4</label>
        <title>Altered membrane fluidity in cancer cell membranes</title>
        <p>Apart from changes in the pattern of the surface charge, membrane fluidity also appears to be altered in tumorigenic cells, though it is not clear if this alteration is uniform throughout all carcinomas. The majority of studies indicate increased fluidity of the cancer cell membrane as described for lymphomas, lung carcinomas and neural tumors (<xref rid="bib0720 bib0765 bib0070 bib0655" ref-type="bibr">Sherbet, 1989; Sok et al., 2002; Campanella, 1992; Rodrigues et al., 2002</xref>). By contrast, it has been reported that cells from solid tumor tissues (e.g. hepatoma) exhibit a lower membrane fluidity than their healthy counterparts (<xref rid="bib0820" ref-type="bibr">van Blitterswijk, 1984</xref>). In this context it is important to note that Sherbet et al. (<xref rid="bib0725" ref-type="bibr">Sherbet and Jackson, 1986</xref>) already suggested that membrane fluidity is not uniform all over the cell itself. This is in accordance with more recent observations showing that some breast and prostate cancer cell lines possess elevated levels of cholesterol-rich lipid rafts, raising the question if in fact only some parts of the cancer membrane comprise increased fluidity by different lateral lipid arrangement (<xref rid="bib0375" ref-type="bibr">Li et al., 2006</xref>). In the case of unaltered total cholesterol content, this would imply a cholesterol-depleted bulk membrane harboring PS that may exhibit higher susceptibility to peptide attack because of its increased fluidity and hence less tightly packed lipids. Interestingly, the metastatic cascade also seems to be influenced by alterations in membrane fluidity. Thus, increased fluidity was reported for metastatic cells (<xref rid="bib0515" ref-type="bibr">Nakazawa and Iwaizumi, 1989</xref>) due to differences in the cholesterol to phospholipid ratio (<xref rid="bib0685" ref-type="bibr">Schroeder and Gardiner, 1984</xref>). According to some reports, resistance to drugs also seems to be related to cell membrane fluidity. <xref rid="bib0465" ref-type="bibr">May et al. (1988)</xref> for example reported that vinblastine resistant leukemic cells possess 50% more cholesterol, corresponding to decreased fluidity, than vinblastine sensitive cells. This finding is supported by higher cholesterol levels in multidrug-resistant ovarian cancer cells (<xref rid="bib0470" ref-type="bibr">Mazzoni and Trave, 1993</xref>). It is evident that knowledge of membrane fluidity (with cholesterol content only being one parameter alongside degree of hydrocarbon chain saturation etc.) should be regarded as an important physical membrane parameter that interferes with insertion of amphipathic peptides being facilitated in more fluid membranes.</p>
      </sec>
      <sec id="sec0050">
        <label>3.5</label>
        <title>Microvilli increasing the cell surface area of cancer cells</title>
        <p>Another important difference between cancer and non-cancer cells is the increase in surface area of tumorigenic cells, triggered by the increase of microvilli on these cells (<xref rid="bib0930 bib0560 bib0175 bib0125" ref-type="bibr">Zwaal and Schroit, 1997; Papo and Shai, 2005; Domagala and Koss, 1980; Chaudhary and Munshi, 1995</xref>). This should be beneficial in the application of membrane-active peptides since efficiency can be increased by enabling the binding of a larger amount of peptides per cell (<xref rid="bib0930 bib0560" ref-type="bibr">Zwaal and Schroit, 1997; Papo and Shai, 2005</xref>). Support for this notion comes from a comparative study on the cytolytic effect of cecropin B on tumor cells such as KG-1 leukemia and Ags stomach carcinoma and non-tumor cells like fibroblasts and red blood cells, which demonstrated that the peptide was more effective on the cancer than normal cells (<xref rid="bib0105" ref-type="bibr">Chan et al., 1998</xref>). Based on scanning electron microscopy data, it was suggested that this may mainly be due to the high population of irregular microvilli on the cell surface of the cancer cells and that the attraction of peptides by microvilli may be one of the main driving forces before membranolysis can be efficiently initiated.</p>
        <p>In summary, accumulation of cationic amphipathic peptides will be triggered by the presence of anionic components on the cell surface as well as by the increase in cell surface owing to increased number of microvilli, while insertion of peptides will be mainly governed by membrane fluidity, which in eukaryotic membranes is largely regulated by its cholesterol content. Therefore, the differences in lipid composition and morphology of cell membranes govern the interaction with membrane-active peptide and furthermore, may also be related to the varying susceptibility of different types of cancer cells against a certain antitumor peptide (<xref rid="bib0370 bib0425" ref-type="bibr">Leuschner and Hansel, 2004; Mader et al., 2005</xref>).</p>
      </sec>
    </sec>
    <sec id="sec0055">
      <label>4</label>
      <title>Mode of action of anticancer peptides</title>
      <p>Two general mechanisms, triggering necrosis or apoptosis by anticancer peptides as a consequence of their membrane related mode of killing of cancer cells, have been discussed (<xref rid="bib0560 bib0060 bib0690" ref-type="bibr">Papo and Shai, 2005; Bhutia and Maiti, 2008; Schweizer, 2009</xref>). Both killing based on necrosis via cell membrane lysis and apoptosis via the mitochondrial lytic effect seems to be dependent on the presence of anionic lipids. As described in Section <xref rid="sec0030" ref-type="sec">3.1</xref>, negatively charged PS located in the outer leaflet of cancer cells can represent such a specific target, e.g. cardiolipin, a major anionic phospholipid of the mitochondrial membrane. Other sources of negatively charged molecules which are also exposed and often overexpressed on non-cancer plasma membranes such as sialylated glycoproteins or heparan sulfate proteoglycans should also be considered when considering the activity and efficacy of cationic anticancer peptides. However, their influence has been studied less systematically and seemingly contradictory effects have been reported in terms of anticancer activity of the peptides (see Sections <xref rid="sec0035 sec0040" ref-type="sec">3.2 and 3.3</xref>). A major role of PS may be deduced from the selective binding of the synthetic host defense-like membranolytic peptide, [<sc>d</sc>]-K<sub>6</sub>L<sub>9</sub>, to PS, which was demonstrated by co-localization of PS and peptides on the outside of cancer cells (<xref rid="bib0565" ref-type="bibr">Papo et al., 2006</xref>). The authors thus suggested that the selectivity of the peptide towards cancer cells stems largely from its binding to surface exposed PS and that killing of the cancer cells occurs via cytoplasmic membrane depolarization. Consequently, it appears that for effective disruption of the cell membrane, peptide–lipid interaction is the crucial step which the peptides need in order to meet the proper structural requirements. Thus, in order to engineer more potent antitumor peptides in respect of efficacy as well as selectivity and thus reduced toxicity, it is necessary to further unravel their molecular mode of action.</p>
      <p>Furthermore, non-membrane related mechanisms have been considered. For example, stimulation of NK cells as well as interferon synthesis by the insect antimicrobial peptide alloferon (<xref rid="bib0135" ref-type="bibr">Chernysh et al., 2002</xref>) or the transcriptional inhibitory effect of melittin and cecropin (<xref rid="bib0880" ref-type="bibr">Winder et al., 1998</xref>) were regarded as being probably due to an indirect mechanism, which is mediated by the ability of the cytolytic peptide to interfere with signal transduction pathways. Tachyplesin conjugated to an integrin homing domain (<xref rid="bib0570 bib0130" ref-type="bibr">Park et al., 1992; Chen et al., 2001</xref>) was further shown to interact with the mitochondrial membranes of cancer cells and to up-regulate members of the death receptor pathway, which suggests that this peptide-conjugate also has more than one effect on cancer cells. Therefore, <xref rid="bib0560" ref-type="bibr">Papo and Shai (2005)</xref> proposed that these observations may imply that in addition to their being active on their own cytolytic peptides may activate or act synergistically with other host defense components in order to clear tumors. Nevertheless, since killing takes place very rapidly it seems quite reasonable to assume that a non-receptor mediated membranolytic killing mechanism is responsible for the majority of anticancer peptides derived from host defense peptides.</p>
      <sec id="sec0060">
        <label>4.1</label>
        <title>Membrane related molecular mechanisms of cell killing</title>
        <p>The discovery that naturally occurring antimicrobial peptides mostly kill bacteria by damaging their cell membrane has initiated much effort in the detailed study of peptide–membrane interaction. The concept of a characteristic lipid composition for a given cell membrane is well accepted and hence the different physicochemical properties of the lipids found in biological membranes allow host defense peptides to discriminate between e.g. bacterial, cancer and non-cancer cell membranes (<xref rid="bib0405 bib0645 bib0390" ref-type="bibr">Lohner et al., 1997; Riedl et al., 2011b; Lohner, 2001</xref>). In a simplified view, these cationic amphipathic peptides will exhibit a higher affinity to cell membranes that expose negatively charged lipids on their outer membrane leaflet. The molecular mechanism(s) of membrane damage mutually depends on the nature of both peptides and membrane lipids (<xref rid="bib0700" ref-type="bibr">Sevcsik et al., 2008</xref>).</p>
        <p>Several models (<xref rid="fig0020" ref-type="fig">Fig. 4</xref>) have been suggested to explain their biological activity (for reviews see e.g. <xref rid="bib0400 bib0395 bib0045 bib0865" ref-type="bibr">Lohner and Blondelle, 2005; Lohner, 2009; Bechinger, 2009; Wimley and Hristova, 2011</xref>). The most frequently discussed mode of action includes the formation of toroidal pores (<xref rid="bib0455 bib0415" ref-type="bibr">Matsuzaki et al., 1996; Ludtke et al., 1996</xref>) and the carpet model (<xref rid="bib0710" ref-type="bibr">Shai, 2002</xref>). In the toroidal pore model peptides, together with the lipid, assemble into a supra-molecular arrangement of high curvature forming a water-filled pore. Although a number of molecules including α-helical and β-sheet type peptides have been shown to adopt such a pore under the given experimental conditions (<xref rid="bib0305" ref-type="bibr">Huang, 2006</xref>), there is little evidence that the majority of these peptides act <italic>in vivo</italic> via transmembrane pores (<xref rid="bib0870" ref-type="bibr">Wimley, 2010</xref>). The carpet model is most commonly cited when explaining membrane disintegration by a non-pore model. In this model, the amphipathic peptides accumulate at the membrane being aligned parallel to the bilayer surface. Once this “peptide carpet” becomes too dense, membrane permeabilization occurs via destabilization of the membrane bilayer (<xref rid="bib0710" ref-type="bibr">Shai, 2002</xref>). Thereby, at the molecular level different scenarios may apply, which were recently summarized in an excellent review by <xref rid="bib0865" ref-type="bibr">Wimley and Hristova (2011)</xref>. Briefly explained, membrane permeabilization has been proposed as being due to (a) peptide induced clustering or phase separation of lipids creating defects at the peptide-rich and peptide-poor domains (<xref rid="bib0395 bib0205 bib0210 bib0215 bib0410 bib0950" ref-type="bibr">Lohner, 2009; Epand et al., 2010; Epand and Epand, 2009, 2011; Lohner and Prenner, 1999; Zweytick et al., 2011b</xref>), (b) the sinking raft model, which allows a formal thermodynamic analysis to predict membrane perturbation (<xref rid="bib0595 bib0600 bib0260 bib0010" ref-type="bibr">Pokorny and Almeida, 2004; Pokorny et al., 2008; Gregory et al., 2008; Almeida and Pokorny, 2009</xref>), (c) disruption of the normally strict segregation of polar and non-polar groups of the lipids driven by the partitioning of an imperfectly amphipathic peptide into the bilayer interface (<xref rid="bib0620 bib0625" ref-type="bibr">Rathinakumar and Wimley, 2008, 2010</xref>) or (d) a detergent-like action in particular at high peptide concentration (<xref rid="bib0300 bib0040 bib0545" ref-type="bibr">Hristova et al., 1997; Bechinger and Lohner, 2006; Ostolaza et al., 1993</xref>). Furthermore, a complex generic phase diagram has recently been developed rationalizing the membrane interactions of cationic amphipathic peptides by their molecular shape to explain in a more general sense the mode of action of these cationic amphipathic peptides (<xref rid="bib0040 bib0045" ref-type="bibr">Bechinger and Lohner, 2006; Bechinger, 2009</xref>). Besides electrostatic interactions, molecular properties of lipids such as their molecular shape and being related to the spontaneous curvature are known to play a significant role for the aggregation state of lipids (<xref rid="bib0315 bib0440 bib0045" ref-type="bibr">Israelachvili et al., 1980; Marsh, 1996; Bechinger, 2009</xref>) and, thus, also to affect interactions of these assemblies with membrane-active peptides. In fact in terms of structural membrane changes, insertion of antimicrobial peptide molecules, some of them also exhibiting antitumor activity such as NK-2 (<xref rid="bib0680" ref-type="bibr">Schröder-Borm et al., 2005</xref>) or lactoferricin derivatives (<xref rid="bib0645" ref-type="bibr">Riedl et al., 2011b</xref>), promoted the formation of inverted hexagonal or bi-continuous cubic phases in membrane mimetic systems (<xref rid="bib0770 bib0860 bib0285 bib0945 bib0950" ref-type="bibr">Staudegger et al., 2000; Willumeit et al., 2005; Hickel et al., 2008; Zweytick et al., 2008, 2011b</xref>).</p>
        <p>Furthermore, solid tumors are discussed as exhibiting an acidic extracellular environment (for a review see <xref rid="bib0265" ref-type="bibr">Griffiths, 1991</xref>). This acidification seems to be a consequence of lactic acid accumulation, which is produced during aerobic and anaerobic glycolysis and, due to inadequate vasculature in growing tumors, its insufficient removal. However, lactic acid accumulation does not seem to be the only reason for the acidification of the extracellular environment of tumors. <xref rid="bib0520" ref-type="bibr">Newell et al. (1993)</xref> reported that glycolysis-deficient cells are also more acidic than cells from normal tissues without accumulating lactic acid above serum levels. In any case, an acidic tumor environment might be a useful “activation” switch for anticancer peptides comprised of amino acids like histidine, which are only positively charged and thus active at low pH (<xref rid="bib0430" ref-type="bibr">Makovitzki et al., 2009</xref>). Such an approach was reported for the synthetic host defense-like lytic peptide [<sc>d</sc>]-K<sub>6</sub>L<sub>9</sub>, where the lysine residues were exchanged by histidine, resulting in reduced systemic toxicity compared to the parent peptide. It was suggested that the pH-dependent activity and lytic mode of action of the His-rich peptide, in hindering development of resistance, will make them potential candidates for treatment of solid tumors. In fact, intra-tumor and systemic inoculation of ([<sc>d</sc>]-H<sub>6</sub>L<sub>9</sub>) significantly reduced the 22RV1 prostate cancer tumor size in a xenograft mice model (<xref rid="bib0430" ref-type="bibr">Makovitzki et al., 2009</xref>).</p>
        <p>In the context of taking advantage of the acidic environment of solid tumors it is worthwhile reporting on pHLIP (pH (Low) Insertion Peptide), a peptide derived from the C-helix of bacteriorhodopsin, although this peptide neither displays a membranolytic mechanism nor is it derived from a host defense peptide. pHLIP shows interesting pH-sensitive properties in that it only forms a transmembrane helix in the acidic environment of solid tumors, whereas at neutral or high pH it is in equilibrium between an unstructured form and bound to the surface of a lipid bilayer (<xref rid="bib0310 bib0635" ref-type="bibr">Hunt et al., 1997; Reshetnyak et al., 2007</xref>). pHLIP itself does not exhibit direct toxicity to cells (<xref rid="bib0630" ref-type="bibr">Reshetnyak et al., 2006</xref>) or mice (<xref rid="bib0020" ref-type="bibr">Andreev et al., 2007</xref>) at concentrations below 50 μM, however, the peptide in its helical form possesses useful drug delivery efficiency facilitating translocation of cell-impermeable polar molecules into the cytoplasm (<xref rid="bib0630 bib0635 bib0020 bib0925 bib0795" ref-type="bibr">Reshetnyak et al., 2006, 2007; Andreev et al., 2007; Zoonens et al., 2008; Thévenin et al., 2009</xref>). One example of efficient drug delivery into cancer cells through translocation with pHLIP is phalloidin toxin, which inhibits cancer cell proliferation after cleavage from pHLIP inside the cells (<xref rid="bib0015" ref-type="bibr">An et al., 2010</xref>).</p>
      </sec>
      <sec id="sec0065">
        <label>4.2</label>
        <title>Non-membrane related mechanisms</title>
        <p>Here, we briefly summarize some mechanisms, which do not involve permeabilization/disruption of plasma or mitochondrial membranes in cancer cells. There is growing evidence that the antimicrobial activity of host defense peptides is not solely related to cell membrane damage but some act caused by immunomodulatory effects (<xref rid="bib0275 bib0185 bib0855" ref-type="bibr">Hancock and Sahl, 2006; Easton et al., 2009; Wieczorek et al., 2010</xref>). Little knowledge is so far available as to whether this may also be the case for the antitumor activity of these cationic amphipathic peptides. In particular in the case of cancers where the immune response is often diminished or strongly suppressed, it was suggested that cancer therapies might be supported by the simultaneous administration of immunoadjuvants, which activate both an innate and acquired immune system response (<xref rid="bib0180" ref-type="bibr">Dredge et al., 2002</xref>). Although many small peptides of microbial origin possess a non-specific immunostimulatory response (for a review see <xref rid="bib0690" ref-type="bibr">Schweizer, 2009</xref>), reports on an immunomodulatory effect of host defense peptides in cancer cells are rare. One example are alloferons, histidine-rich peptides from insects shown to stimulate natural killer cells of human peripheral blood lymphocytes and to induce synthesis of interferon in mice models (<xref rid="bib0135" ref-type="bibr">Chernysh et al., 2002</xref>). This cytokine-like modulating property resulted in antitumor resistance.</p>
        <p>Specific targets have so far only been reported for a few anticancer peptides. PR-39, a peptide of the cathelicidin family which is rich in proline and arginine residues, can translocate into the cytosolic compartment of cells without permeabilizing the plasma membrane where it interacts with proteins containing SH3-binding motifs (<xref rid="bib0110 bib0790" ref-type="bibr">Chan and Gallo, 1998; Tanaka et al., 2001</xref>). Experiments using derivatives of PR-39 indicated that the N-terminal arginine is crucial for binding to the SH3-domain and subsequent induction of syndecan-1 production (<xref rid="bib0115" ref-type="bibr">Chan et al., 2001</xref>). Indeed, elevated levels of syndecan-1 were observed in treatment of human hepatocellular carcinoma cells with either PR-39 or upon transfection of this cell line with the PR-39 gene (<xref rid="bib0535" ref-type="bibr">Ohtake et al., 1999</xref>). Expression of syndecan-1 has been related to inhibition of cell invasion (<xref rid="bib0380" ref-type="bibr">Liebersbach and Sanderson, 1994</xref>) and thus it was suggested that this linear cationic peptide may suppress the invasive activity of these cancer cells therefore preventing metastasis (<xref rid="bib0535" ref-type="bibr">Ohtake et al., 1999</xref>). Another target of many anticancer drugs is tubulin, which was also shown to be the site of action for linear peptides derived from the host defense-like peptide dolastatin 10 (US Pat. No. 4,816,444) or dolastatin 15 (EP-A-398558) (<xref rid="bib0745" ref-type="bibr">Simmons et al., 2005</xref>). Thereby, the mechanism of action, as for all antitumor tubulin ligands, involves the perturbation of microtubule dynamics during the G2/M phase of cell division and subsequent entry into apoptosis (<xref rid="bib0155" ref-type="bibr">Davis et al., 1999</xref>).</p>
        <p>Finally, a specific case was reported for bee venom melittin, which preferentially counter-selects mammalian cells with the overexpressed <italic>ras</italic> oncogene, where it acts through hyperactivation of phospholipase A<sub>2</sub> (<xref rid="bib0715" ref-type="bibr">Sharma, 1992</xref>). It should be noted, however, that melittin is also known for its toxicity to mammalian cells (e.g. (<xref rid="bib0270" ref-type="bibr">Habermann and Jentsch, 1967</xref>)). In fact, for <italic>in vivo</italic> studies a melittin/avidin conjugate was used, which did not exert its anticancer activity by membranolysis but by targeting cancer cells with high matrix metalloproteinase 2 (<xref rid="bib0290" ref-type="bibr">Holle et al., 2003</xref>) as described in Section <xref rid="sec0080" ref-type="sec">5.2</xref>.</p>
      </sec>
    </sec>
    <sec id="sec0070">
      <label>5</label>
      <title><italic>In vivo</italic> studies of anticancer peptides</title>
      <p>Based on successful <italic>in vitro</italic> experiments, a number of peptides have also been tested <italic>in vivo</italic> to explore their therapeutic potential (<xref rid="tbl0010" ref-type="table">Table 2</xref>). In addition to the administration of anticancer peptides <italic>per se</italic>, strategies have been developed that may improve pharmacokinetics and/or selectivity and hence reduce toxicity. This includes the application of vector-mediated delivery of genes encoding membranolytic peptides and the use of homing domains transporting the anticancer peptides into the cytosolic compartment of cancer cells. Some of the respective <italic>in vivo</italic> studies are briefly described below.</p>
      <sec id="sec0075">
        <label>5.1</label>
        <title>Anticancer activity of peptides related to membrane damage</title>
        <p>Magainins, originally isolated from the skin of the African clawed frog, <italic>Xenopus laevis</italic> (<xref rid="bib0910" ref-type="bibr">Zasloff, 1987</xref>), were among the first peptides to be tested for their <italic>in vivo</italic> anticancer activity. Magainin 2 was shown to exhibit an amphiphilic α-helical structure that facilitates the formation of ion-permeable pores in membranes, consequently inducing depolarization and cytolysis (<xref rid="bib0150" ref-type="bibr">Cruciani et al., 1991</xref>). <xref rid="bib0035" ref-type="bibr">Baker et al. (1993)</xref> demonstrated that magainin analogues were able to elevate the survival level of animals with ascites-producing tumors. Furthermore, magainin 2 has been tested for local treatment in a subcutaneous xenograft model of melanoma in nude mice, where it completely eliminated the tumor with only minimal damage to surrounding tissue (<xref rid="bib0755" ref-type="bibr">Soballe et al., 1995</xref>).</p>
        <p>Another prominent member of anticancer peptides is bovine lactoferricin (<xref rid="bib0245" ref-type="bibr">Gifford et al., 2005</xref>), which is generated from lactoferrin through pepsin cleavage. Unlike magainins, bLFcin possesses an acyclic twisted antiparallel β-sheet structure due to a disulfide bridge between two cysteine residues (<xref rid="bib0830" ref-type="bibr">Vogel et al., 2002</xref>). Systematic studies on bLFcin derivatives revealed some parameters of importance for antitumor activity such as the need for high net positive charge (+7 as compared to +4 for antimicrobial activity) and clear cationic and hydrophobic sectors (amphipathicity) (<xref rid="bib0900 bib0895" ref-type="bibr">Yang et al., 2004, 2003</xref>). Furthermore, the requirement of a stabilized secondary structure may be deduced from the higher activity of the cyclic peptide (<xref rid="bib0200" ref-type="bibr">Eliassen et al., 2002</xref>), which showed a clearer partitioning of the cationic and hydrophobic faces (<xref rid="bib0530" ref-type="bibr">Nguyen et al., 2005</xref>). As this property is less important for antimicrobial activity, it was suggested that it indicates a constraint for the peptide to traverse mammalian membranes (<xref rid="bib0245" ref-type="bibr">Gifford et al., 2005</xref>). <xref rid="bib0905" ref-type="bibr">Yoo et al. (1997)</xref> demonstrated that the peptide inhibits liver and lung metastasis in mice. Additionally, bLFcin showed antiangiogenic activity leading to suppression of tumor growth. <italic>In vivo</italic> studies with bLFcin on fibrosarcoma, melanoma and colon carcinoma tumors revealed massive necrosis of the tumor tissue after exposure to the peptide (<xref rid="bib0200" ref-type="bibr">Eliassen et al., 2002</xref>). <xref rid="bib0195" ref-type="bibr">Eliassen et al. (2006)</xref> also showed that bLFcin significantly inhibits tumor growth of neuroblastoma xenografts in nude rats. Clarification of the mechanism revealed that bLFcin induces apoptosis in human tumor cells through a pathway mediated by production of the intracellular ROS and activation of Ca<sup>2+</sup>/Mg<sup>2+</sup>-dependent endonucleases (<xref rid="bib0905" ref-type="bibr">Yoo et al., 1997</xref>), which was partially confirmed by studies carried out by <xref rid="bib0425" ref-type="bibr">Mader et al. (2005)</xref>, who also documented the mitochondrial pathway of apoptosis for bLFcin. Other studies reported that induction of apoptotic or necrotic cell death was dependent on the concentration of the peptide (<xref rid="bib0540 bib0195" ref-type="bibr">Onishi et al., 2008; Eliassen et al., 2006</xref>). Recently, it was shown that <italic>in vitro</italic> treatment with bLFcin killed Raji and Ramos human B-lymphoma cells via a caspase-independent apoptotic pathway being more efficient at low serum concentration of the peptide (<xref rid="bib0240" ref-type="bibr">Furlong et al., 2010</xref>). Notably, in the presence of exogenous bovine serum albumin the activity was inhibited, which suggests partial neutralization of the cationic peptide by anionic serum components as described earlier for the inhibition of the tumoricidal activity of amphiphilic alpha helical peptides (<xref rid="bib0580" ref-type="bibr">Peck-Miller et al., 1993</xref>). Nevertheless, immune-deficient SCID/beige mice exhibited extended survival using systemic administration of bLFcin underlining the potential of this peptide for further development as novel anticancer agent.</p>
        <p>Gomesin (Gm), an antimicrobial peptide isolated from the hemocytes of the unchallenged Brazilian spider <italic>Acanthoscurria gomesiana</italic>, also exhibits anticancer activity (<xref rid="bib0740" ref-type="bibr">Silva et al., 2000</xref>). This cationic peptide adopts a hairpin-like two-stranded antiparallel β-sheet structure, which is maintained by two internal disulfide bridges (<xref rid="bib0435" ref-type="bibr">Mandard et al., 2002</xref>). Topical treatment of subcutaneous murine melanoma with gomesin significantly retarded tumor growth and increased the number of animals with tumors below a critical size (<xref rid="bib0660" ref-type="bibr">Rodrigues et al., 2008</xref>). Importantly, Gm did not exhibit any toxic effect on the peripheral healthy skin of mice after repeated applications of the peptide. Gm does not kill tumor cells through apoptosis but rather through induction of morphologic cell alterations with increased granularity, loss of cytoplasmic content by membrane permeabilization, and partial collapse of the proton gradient (<xref rid="bib0660" ref-type="bibr">Rodrigues et al., 2008</xref>).</p>
        <p>Polybia-MPI (MPI) is an anticancer peptide derived from the venom of social wasp <italic>Polybia paulista</italic>. In order to improve the activity and stability of MPI, the C-terminal amide of the peptide was replaced by a thioamide group (MPI-1) (<xref rid="bib0920" ref-type="bibr">Zhang et al., 2010</xref>). Indeed, MPI-1 is more efficient in suppresssing tumor growth of sarcoma xenograft in mice than MPI, which was attributed to its higher serum stability. However, the modification did not affect the cytotoxic behavior of the peptide. <italic>In vitro</italic> studies provide evidence of killing caused by necrosis as a result of acute cell injury, swelling and bursting via disruption of the membrane or formation of transmembrane pores (<xref rid="bib0845" ref-type="bibr">Wang et al., 2009c</xref>).</p>
        <p>An alternative approach for <italic>in vivo</italic> use of membranolytic peptides to maintain therapeutic levels and reduce cytotoxicity was suggested by <xref rid="bib0880" ref-type="bibr">Winder et al. (1998)</xref> and involving the introduction of vector-mediated delivery of genes encoding cecropin or melittin into a human bladder carcinoma derived cell line (<xref rid="bib0880" ref-type="bibr">Winder et al., 1998</xref>). The resultant cell clones were analyzed for tumorigenicity in nude mice showing that expression of cecropin resulted in either a complete loss of tumorigenicity in some clones or reduced tumorigenicity as measured by latency of tumor formation. Similarly, a plasmid that expressed secretable human α-defensin-1, also known as the human neutrophil peptide-1 (HNP1) was used in gene therapy of a human lung adenocarcinoma xenograft in nude mice (<xref rid="bib0890" ref-type="bibr">Xu et al., 2008</xref>). In this study, <xref rid="bib0890" ref-type="bibr">Xu et al. (2008)</xref> showed that HNP1 can be intracellularily expressed in tumor cells resulting in significant inhibition of tumor growth by induction of apoptosis.</p>
      </sec>
      <sec id="sec0080">
        <label>5.2</label>
        <title>Anticancer agents based on anticancer peptide-conjugates</title>
        <p>Melittin, extracted from the European honey bee <italic>Apis mellifera</italic>, is a mostly α-helical peptide assumed to induce cell lysis by pore formation (<xref rid="bib0810 bib0460" ref-type="bibr">Tosteson and Tosteson, 1981; Matsuzaki et al., 1997</xref>). Since melittin is highly toxic to red blood cells and untransformed cells, a melittin/avidin conjugate was designed to gain an inactive peptide towards healthy cells as it specifically targets cancer cells with high matrix metalloproteinase 2 (MMP2) activity (<xref rid="bib0290" ref-type="bibr">Holle et al., 2003</xref>). MMP2 is known to be overexpressed in several cancers and tumor microvascular endothelial cells and has the ability to reactivate peptide activity by cleavage of the conjugate at the tumor site. <italic>In vivo</italic> studies showed that the size of B16 tumors in mice decreased significantly after treatment with the melittin/avidin conjugate. Activity of the conjugate most probably arises from its ability to target tumor vasculature since the level of cell lysis in cultured cells was relatively low (<xref rid="bib0290" ref-type="bibr">Holle et al., 2003</xref>).</p>
        <p>Tachyplesin, a peptide isolated from hemocytes of the horseshoe crab (<italic>Tachypleus tridentatus</italic>), exhibits a structure with exposed basic amino acids on the peptide surface (<xref rid="bib0505" ref-type="bibr">Nakamura et al., 1988</xref>), which enables binding to anionic phospholipids (<xref rid="bib0570 bib0345" ref-type="bibr">Park et al., 1992; Katsu et al., 1993</xref>). The peptide was shown to have anticancer activity <italic>in vivo</italic> in a B16 mouse model (<xref rid="bib0130" ref-type="bibr">Chen et al., 2001</xref>). In this study, a synthetic tachyplesin was conjugated to the integrin homing domain RGB, which enables internalization of the peptide.</p>
      </sec>
      <sec id="sec0085">
        <label>5.3</label>
        <title>Anti-proliferative peptides</title>
        <p>Dolastatin 10 (US Pat. No. 4,816,444) derived from the family of dolastatins, a peptide isolated from the marine shell-less mollusk <italic>Dolabela auricularia</italic>, completed Phase II trial against indolent lymphoma, Waldenstrom's macroglobulinemia and chronic lymphocytic leukemia in 2000 (<xref rid="bib0745" ref-type="bibr">Simmons et al., 2005</xref>). At the time of discovery it was shown to be the most potent anti-proliferative agent against murine PS leukemia cells (<xref rid="bib0590" ref-type="bibr">Pettit et al., 1987</xref>). Eventually, the peptide had to be dropped from clinical trials because of moderate peripheral neuropathy in 40% of patients. Therefore, derivatives of dolastatin 10, like TZT-1027 (Soblidotin) (<xref rid="bib0490" ref-type="bibr">Miyazaki et al., 1995</xref>) or of dolastatin 15 (antimitotic), like ILX-651 (Synthadotin) (<xref rid="bib0190" ref-type="bibr">Ebbinghaus et al., 2004</xref>), which show reduced toxicity but yet potent antitumor activity have been further explored in clinical studies.</p>
      </sec>
    </sec>
    <sec id="sec0090">
      <label>6</label>
      <title>Challenges for the development of host defense peptides as novel anticancer agents</title>
      <p>Interestingly, despite numerous successful <italic>in vivo</italic> studies none of the membrane-active host defense peptides has so far made it on to the market. There may be several reasons for this and their development as novel anticancer agent may predominantly be hampered by the poor bioavailability and potential toxicity of such peptides (<xref rid="bib0275" ref-type="bibr">Hancock and Sahl, 2006</xref>). Peptide degradation in serum owing to the presence of proteases is a major obstacle, which besides unspecific binding to serum components also limits the half time of these molecules in serum. In order to improve the pharmacodynamic properties, different strategies may be applied to achieve enhanced cell specificity and serum stability.</p>
      <sec id="sec0095">
        <label>6.1</label>
        <title>Enhancing selectivity to further reduce cytotoxicity</title>
        <p>Not all host defense peptides showing antitumor activity are sufficiently selective against cancer cells. Accordingly, a more detailed knowledge of their structure–activity relationship is required in order to understand the molecular peptide parameters for the design of promising novel antitumor agents. As outlined above, host defense peptides exhibit great structural diversity yet share some common features. They are typically 10–40 amino acids long and positively charged (net charge of +2 to +9). While differing in the percentage of hydrophobic residues, these peptides share an amphiphilic character, i.e. they have the ability to adopt a structure in which hydrophobic and polar/charged residues are spatially organized in discrete sectors of the molecule. Although host defense peptides belong to different structural classes, they often exhibit an intrinsic flexibility and structural adaptability, which are thought to be responsible for different modes of interaction with membrane bilayers (<xref rid="bib0335" ref-type="bibr">Joanne et al., 2009</xref>). Thus net charge, amphipathicity, hydrophobicity, and structural propensity are among the most important physicochemical and structural parameters that govern the ability of these peptides to interact with cell membranes. A statistical analysis of the antitumor peptides listed in the Antimicrobial Peptide Data Base (<xref rid="bib0850 bib0840" ref-type="bibr">Wang and Wang, 2004; Wang et al., 2009b</xref>) in terms of secondary structure, length of the peptide, distribution of charged and hydrophobic amino acid residues and determination of hydrophobicity expressed as transfer free energy of peptides from water to <italic>n</italic>-octanol (Δ<italic>G</italic><sub>woct</sub>) (<xref rid="bib0875" ref-type="bibr">Wimley et al., 1996</xref>) show that these parameters can vary within a wide range (<xref rid="fig0025" ref-type="fig">Fig. 5</xref>). It is interesting to note that there is still a large fraction of peptides with unknown structure (∼39%) being comparable to the fraction of peptides with α-helical structure (∼34%), which seems to be the predominant one. However, as can be deduced from <xref rid="tbl0005 tbl0010" ref-type="table">Tables 1 and 2</xref> there have been not less peptides tested successfully in <italic>in vitro</italic> and <italic>in vivo</italic> studies, which exhibit a β-sheet structure, although these peptides account only for ∼2% of the total antitumor peptides listed. Pair correlations between peptide length and charge as well as peptide length and hydrophobicity indicate again that even for a given peptide length these parameters can vary widely being more apparent for the distribution of the net charge (<xref rid="fig0030" ref-type="fig">Fig. 6</xref>). For a meaningful interpretation of these data one would also need to consider the antitumor activity and cell specificity of the peptides. However, this cannot be performed on this set of data, as the peptides listed in the Antimicrobial Peptide Data Base (<xref rid="bib0850 bib0840" ref-type="bibr">Wang and Wang, 2004; Wang et al., 2009b</xref>) were tested against different cancer cells and healthy mammalian cells using also different protocols. But a cluster analysis of a database of 158 amphipathic α-helical peptides, from which the activity spectrum was determined, revealed structural characteristics of anticancer peptides (<xref rid="bib0165" ref-type="bibr">Dennison et al., 2010</xref>). This database was constructed using data presented by Owen (US Patent 6,875,744), and contained 14 peptides, which showed selectivity for cancer cell lines only, 123 peptides showing cytotoxicity also to non-cancer cells and 21 inactive peptides. Three-dimensional clustering techniques were used to group these peptides with respect to similarity in net positive charge, hydrophobicity and hydrophobic moment producing 21 clusters. The observation that the inactive peptides were found across seven clusters highlights the fact that these three parameters alone cannot be used as predictors of activity. However, as hydrophobicity of peptides is important for membrane penetration, an extended hydrophobic moment plot analysis was also performed. Although peptides with arc sizes &gt;270° appeared to be less toxic, statistical analysis was unable to establish a direct correlation between arc size and toxicity. Furthermore, using this approach it was predicted that over 50% of the active peptides would be surface active. This suggests that amphiphilicity is a key driver of the membrane interactions for these peptides. Thereby, peptides showing cancer cell specificity fell within a narrow range of amphiphilicity of 0.53–0.78 and had no tilted helical peptide structure, which within the analysis was more commonly found for peptides being toxic to both cancer and non-cancer cells. Such a tilted structure has already been previously associated with relatively non-specific means of cell membrane lysis (<xref rid="bib0295" ref-type="bibr">Hoskin and Ramamoorthy, 2008</xref>). This cluster analysis in conjunction with an earlier study carried out by the same group (<xref rid="bib0160" ref-type="bibr">Dennison et al., 2006</xref>) suggests that the interplay of a range of physicochemical characteristics rather than any single overriding factor determines the biological activity of these peptides. Furthermore, to add to the complexity of the system one must bear in mind that the lipid composition of the target membrane should not be neglected as it in turn strongly affects the penetration behavior of peptides. Therefore, application of newly developed technologies for high-throughput screening as recently described in regard to antimicrobial peptides (<xref rid="bib0065" ref-type="bibr">Blondelle and Lohner, 2010</xref>) may be beneficial in unraveling the molecular parameters making anticancer peptides more suitable for clinical use, i.e. exhibiting high specificity and activity, low susceptibility to proteolysis and reduced toxicity.</p>
      </sec>
      <sec id="sec0100">
        <label>6.2</label>
        <title>Improving serum stability</title>
        <p>The <italic>in vivo</italic> potency of antitumor peptides is often hindered by proteolysis of the peptides, which reduces their half time in serum and hence bioavailability. One strategy used to overcome this problem is the application of vector-mediated delivery of genes that encode the active anticancer peptide (<xref rid="bib0880" ref-type="bibr">Winder et al., 1998</xref>) as outlined in Section <xref rid="sec0075" ref-type="sec">5.1</xref>. Another simple but efficient modification is the incorporation of <sc>d</sc>-amino acids or the replacement of all naturally occurring <sc>l</sc>-amino acids by its diastereomer (<xref rid="bib0560" ref-type="bibr">Papo and Shai, 2005</xref>). Early studies on magainin 2 and its all <sc>d</sc>-amino acid analogue MSI-238 demonstrated the feasibility of this approach (<xref rid="bib0035" ref-type="bibr">Baker et al., 1993</xref>). Both peptides were found to be active against P388 leukemia, S180 ascites and spontaneous ovarian tumor of mice upon intra-peritoneal injection of peptides, but with the all-D peptide showing significantly higher <italic>in vitro</italic> activity than the all-L peptide (<xref rid="bib0035" ref-type="bibr">Baker et al., 1993</xref>). A series of studies were initiated using systematically de novo-designed antimicrobial peptides composed of both <sc>d</sc>- and <sc>l</sc>-amino acids mimicking the lytic activity of host defense peptides (<xref rid="bib0555" ref-type="bibr">Papo and Shai, 2003</xref>). The resulting diastereomeric peptides lost their cytotoxic effect against normal cells but preserved anticancer activity with reduced serum inactivation and enzymatic degradation <italic>in vivo</italic>. For instance, one specific diastereomer composed of 15 amino acids ([<sc>d</sc>]-K<sub>6</sub>L<sub>9</sub>) showed selectivity to primary and metastatic tumors in human prostate and breast xenografts when administered systemically (<xref rid="bib0550 bib0565" ref-type="bibr">Papo et al., 2004, 2006</xref>). A histopathological evaluation revealed that the diastereomer did not cause any damage to organs of mice emphasizing the potential for such peptides to be developed for therapeutic application.</p>
      </sec>
    </sec>
    <sec id="sec0105">
      <label>7</label>
      <title>Perspectives</title>
      <p>Cancer treatment with chemotherapeutics still has many severe side effects and can induce drug resistance thus adversely affecting their successful use. Therefore, novel therapeutic approaches with improved cancer cell selectivity and thus reduced toxicity as well as hindered resistance development are urgently needed as has been observed for membrane-active host defense peptides in a number of <italic>in vivo</italic> studies (see Section <xref rid="sec0070" ref-type="sec">5</xref>). It is also advantageous that they have excellent tumor tissue penetration, which enables them not only to reach primary but also metastatic tumor sites. However, despite the wealth of information the molecular basis for selective targeting of cancer cells and the mechanism of cell killing by host defense peptides remain questions to be solved. Since there is a wide variety of host defense peptides yet many of them do not possess sufficient antitumor activity, optimization of peptides including innovative types of peptide modification to fine-tune their selective interaction with their target cell membrane together with a profound knowledge of their characteristic lipid composition are needed in order to attain a highly active and specific peptide. Biophysical studies considering the peptides as well as membrane characteristics will provide new insights for the rationale design of anticancer peptides. The progress may be facilitated by recent advances in high-throughput screening techniques that can also be implemented in academic laboratories. Based on such knowledge, the field of peptidomimetics may offer alternative means for the development of anticancer drugs with optimized pharmacodynamic profiles. In conclusion, these strategies are expected to yield novel anticancer drugs with improved properties with respect to selectivity and thus reduced toxicity, as well as to hindered development of drug resistance. These peptides may also be used in combination with chemotherapeutics as some peptides have shown synergy with classical chemotherapy (<xref rid="bib0560" ref-type="bibr">Papo and Shai, 2005</xref>). Achieving this goal would represent a major advancement in cancer treatment.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="bib0005">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Albert</surname>
              <given-names>M.L.</given-names>
            </name>
            <name>
              <surname>Sauter</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Bhardwaj</surname>
              <given-names>N.</given-names>
            </name>
          </person-group>
          <article-title>Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs</article-title>
          <source>Nature</source>
          <volume>392</volume>
          <year>1998</year>
          <fpage>86</fpage>
          <lpage>89</lpage>
          <pub-id pub-id-type="pmid">9510252</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0010">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Almeida</surname>
              <given-names>P.F.</given-names>
            </name>
            <name>
              <surname>Pokorny</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Mechanisms of antimicrobial, cytolytic, and cell-penetrating peptides: from kinetics to thermodynamics</article-title>
          <source>Biochemistry</source>
          <volume>48</volume>
          <year>2009</year>
          <fpage>8083</fpage>
          <lpage>8093</lpage>
          <pub-id pub-id-type="pmid">19655791</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0015">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>An</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Wijesinghe</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Andreev</surname>
              <given-names>O.A.</given-names>
            </name>
            <name>
              <surname>Reshetnyak</surname>
              <given-names>Y.K.</given-names>
            </name>
            <name>
              <surname>Engelman</surname>
              <given-names>D.M.</given-names>
            </name>
          </person-group>
          <article-title>pH-(low)-insertion-peptide (pHLIP) translocation of membrane impermeable phalloidin toxin inhibits cancer cell proliferation</article-title>
          <source>Proc. Natl. Acad. Sci. U.S.A.</source>
          <volume>107</volume>
          <year>2010</year>
          <fpage>20246</fpage>
          <lpage>20250</lpage>
          <pub-id pub-id-type="pmid">21048084</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0020">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Andreev</surname>
              <given-names>O.A.</given-names>
            </name>
            <name>
              <surname>Dupuy</surname>
              <given-names>A.D.</given-names>
            </name>
            <name>
              <surname>Segala</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Sandugu</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Serra</surname>
              <given-names>D.A.</given-names>
            </name>
            <name>
              <surname>Chichester</surname>
              <given-names>C.O.</given-names>
            </name>
            <name>
              <surname>Engelman</surname>
              <given-names>D.M.</given-names>
            </name>
            <name>
              <surname>Reshetnyak</surname>
              <given-names>Y.K.</given-names>
            </name>
          </person-group>
          <article-title>Mechanism and uses of a membrane peptide that targets tumors and other acidic tissues in vivo</article-title>
          <source>Proc. Natl. Acad. Sci. U.S.A.</source>
          <volume>104</volume>
          <year>2007</year>
          <fpage>7893</fpage>
          <lpage>7898</lpage>
          <pub-id pub-id-type="pmid">17483464</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0025">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aviel-Ronen</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Lau</surname>
              <given-names>S.K.</given-names>
            </name>
            <name>
              <surname>Pintilie</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Lau</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Tsao</surname>
              <given-names>M.S.</given-names>
            </name>
            <name>
              <surname>Jothy</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Glypican-3 is overexpressed in lung squamous cell carcinoma, but not in adenocarcinoma</article-title>
          <source>Mod. Pathol.</source>
          <volume>21</volume>
          <year>2008</year>
          <fpage>817</fpage>
          <lpage>825</lpage>
          <pub-id pub-id-type="pmid">18469798</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0030">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bafna</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Kaur</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Batra</surname>
              <given-names>S.K.</given-names>
            </name>
          </person-group>
          <article-title>Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells</article-title>
          <source>Oncogene</source>
          <volume>29</volume>
          <year>2010</year>
          <fpage>2893</fpage>
          <lpage>2904</lpage>
          <pub-id pub-id-type="pmid">20348949</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0035">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Baker</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Maloy</surname>
              <given-names>W.L.</given-names>
            </name>
            <name>
              <surname>Zasloff</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Jacob</surname>
              <given-names>L.S.</given-names>
            </name>
          </person-group>
          <article-title>Anticancer efficacy of Magainin2 and analogue peptides</article-title>
          <source>Cancer Res.</source>
          <volume>53</volume>
          <year>1993</year>
          <fpage>3052</fpage>
          <lpage>3057</lpage>
          <pub-id pub-id-type="pmid">8319212</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0040">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bechinger</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Lohner</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Detergent-like actions of linear amphipathic cationic antimicrobial peptides</article-title>
          <source>Biochim. Biophys. Acta</source>
          <volume>1758</volume>
          <year>2006</year>
          <fpage>1529</fpage>
          <lpage>1539</lpage>
          <pub-id pub-id-type="pmid">16928357</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0045">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bechinger</surname>
              <given-names>B.</given-names>
            </name>
          </person-group>
          <article-title>Rationalizing the membrane interactions of cationic amphipathic antimicrobial peptides by their molecular shape</article-title>
          <source>Curr. Opin. Colloid Interface Sci.</source>
          <volume>14</volume>
          <year>2009</year>
          <fpage>349</fpage>
          <lpage>355</lpage>
        </element-citation>
      </ref>
      <ref id="bib0050">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bevers</surname>
              <given-names>E.M.</given-names>
            </name>
            <name>
              <surname>Comfurius</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Dekkers</surname>
              <given-names>D.W.</given-names>
            </name>
            <name>
              <surname>Harmsma</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Zwaal</surname>
              <given-names>R.F.</given-names>
            </name>
          </person-group>
          <article-title>Regulatory mechanisms of transmembrane phospholipid distributions and pathophysiological implications of transbilayer lipid scrambling</article-title>
          <source>Lupus</source>
          <volume>7</volume>
          <issue>suppl. 2</issue>
          <year>1998</year>
          <fpage>S126</fpage>
          <lpage>S131</lpage>
          <pub-id pub-id-type="pmid">9814689</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0055">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bevers</surname>
              <given-names>E.M.</given-names>
            </name>
            <name>
              <surname>Comfurius</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Zwaal</surname>
              <given-names>R.F.</given-names>
            </name>
          </person-group>
          <article-title>Regulatory mechanisms in maintenance and modulation of transmembrane lipid asymmetry: pathophysiological implications</article-title>
          <source>Lupus</source>
          <volume>5</volume>
          <year>1996</year>
          <fpage>480</fpage>
          <lpage>487</lpage>
          <pub-id pub-id-type="pmid">8902787</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0060">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bhutia</surname>
              <given-names>S.K.</given-names>
            </name>
            <name>
              <surname>Maiti</surname>
              <given-names>T.K.</given-names>
            </name>
          </person-group>
          <article-title>Targeting tumors with peptides from natural sources</article-title>
          <source>Trends Biotechnol.</source>
          <volume>26</volume>
          <year>2008</year>
          <fpage>210</fpage>
          <lpage>217</lpage>
          <pub-id pub-id-type="pmid">18295917</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0065">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Blondelle</surname>
              <given-names>S.E.</given-names>
            </name>
            <name>
              <surname>Lohner</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Optimization and high-throughput screening of antimicrobial peptides</article-title>
          <source>Curr. Pharm. Des.</source>
          <volume>16</volume>
          <year>2010</year>
          <fpage>3204</fpage>
          <lpage>3211</lpage>
          <pub-id pub-id-type="pmid">20687884</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0070">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Campanella</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Membrane lipids modifications in human gliomas of different degree of malignancy</article-title>
          <source>J. Neurosurg. Sci.</source>
          <volume>36</volume>
          <year>1992</year>
          <fpage>11</fpage>
          <lpage>25</lpage>
          <pub-id pub-id-type="pmid">1323645</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0075">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Capranico</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Kohn</surname>
              <given-names>K.W.</given-names>
            </name>
            <name>
              <surname>Pommier</surname>
              <given-names>Y.</given-names>
            </name>
          </person-group>
          <article-title>Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin</article-title>
          <source>Nucleic Acids Res.</source>
          <volume>18</volume>
          <year>1990</year>
          <fpage>6611</fpage>
          <lpage>6619</lpage>
          <pub-id pub-id-type="pmid">2174543</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0080">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carraway</surname>
              <given-names>K.L.</given-names>
            </name>
            <name>
              <surname>Price-Schiavi</surname>
              <given-names>S.A.</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Komatsu</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Membrane mucins and breast cancer</article-title>
          <source>Cancer Control</source>
          <volume>6</volume>
          <year>1999</year>
          <fpage>613</fpage>
          <lpage>614</lpage>
          <pub-id pub-id-type="pmid">10756395</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0085">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cassidy</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Misset</surname>
              <given-names>J.L.</given-names>
            </name>
          </person-group>
          <article-title>Oxaliplatin-related side effects: characteristics and management</article-title>
          <source>Semin. Oncol.</source>
          <volume>29</volume>
          <year>2002</year>
          <fpage>11</fpage>
          <lpage>20</lpage>
          <pub-id pub-id-type="pmid">12422304</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0090">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cazet</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Julien</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Bobowski</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Krzewinski-Recchi</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Harduin-Lepers</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Groux-Degroote</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Delannoy</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Consequences of the expression of sialylated antigens in breast cancer</article-title>
          <source>Carbohydr. Res.</source>
          <volume>345</volume>
          <year>2010</year>
          <fpage>1377</fpage>
          <lpage>1383</lpage>
          <pub-id pub-id-type="pmid">20231016</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0095">
        <mixed-citation publication-type="other">CBTRUS, 2008. Statistical Report: Primary Brain Tumors in the United States, 2000-2004. Central Brain Tumor Registry of the United States, 2008.</mixed-citation>
      </ref>
      <ref id="bib0100">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chaires</surname>
              <given-names>J.B.</given-names>
            </name>
          </person-group>
          <article-title>Thermodynamics of the daunomycin-DNA interaction: ionic strength dependence of the enthalpy and entropy</article-title>
          <source>Biopolymers</source>
          <volume>24</volume>
          <year>1985</year>
          <fpage>403</fpage>
          <lpage>419</lpage>
          <pub-id pub-id-type="pmid">3978225</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0105">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chan</surname>
              <given-names>S.C.</given-names>
            </name>
            <name>
              <surname>Hui</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>H.M.</given-names>
            </name>
          </person-group>
          <article-title>Enhancement of the cytolytic effect of anti-bacterial cecropin by the microvilli of cancer cells</article-title>
          <source>Anticancer Res.</source>
          <volume>18</volume>
          <year>1998</year>
          <fpage>4467</fpage>
          <lpage>4474</lpage>
          <pub-id pub-id-type="pmid">9891511</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0110">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chan</surname>
              <given-names>Y.R.</given-names>
            </name>
            <name>
              <surname>Gallo</surname>
              <given-names>R.L.</given-names>
            </name>
          </person-group>
          <article-title>PR-39, a syndecan-inducing antimicrobial peptide, binds and affects p130Cas</article-title>
          <source>J. Biol. Chem.</source>
          <volume>273</volume>
          <year>1998</year>
          <fpage>28978</fpage>
          <lpage>28985</lpage>
          <pub-id pub-id-type="pmid">9786902</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0115">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chan</surname>
              <given-names>Y.R.</given-names>
            </name>
            <name>
              <surname>Zanetti</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Gennaro</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Gallo</surname>
              <given-names>R.L.</given-names>
            </name>
          </person-group>
          <article-title>Anti-microbial activity and cell binding are controled by sequence determinants in the anti-microbial peptide PR-39</article-title>
          <source>J. Invest. Dermatol.</source>
          <volume>116</volume>
          <year>2001</year>
          <fpage>230</fpage>
          <lpage>235</lpage>
          <pub-id pub-id-type="pmid">11179998</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0120">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chapman</surname>
              <given-names>P.B.</given-names>
            </name>
            <name>
              <surname>Einhorn</surname>
              <given-names>L.H.</given-names>
            </name>
            <name>
              <surname>Meyers</surname>
              <given-names>M.L.</given-names>
            </name>
            <name>
              <surname>Saxman</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Destro</surname>
              <given-names>A.N.</given-names>
            </name>
            <name>
              <surname>Panageas</surname>
              <given-names>K.S.</given-names>
            </name>
            <name>
              <surname>Begg</surname>
              <given-names>C.B.</given-names>
            </name>
            <name>
              <surname>Agarwala</surname>
              <given-names>S.S.</given-names>
            </name>
            <name>
              <surname>Schuchter</surname>
              <given-names>L.M.</given-names>
            </name>
            <name>
              <surname>Ernstoff</surname>
              <given-names>M.S.</given-names>
            </name>
            <name>
              <surname>Houghton</surname>
              <given-names>A.N.</given-names>
            </name>
            <name>
              <surname>Kirkwood</surname>
              <given-names>J.M.</given-names>
            </name>
          </person-group>
          <article-title>Phase III multicenter randomized trial of the dartmouth regimen versus dacarbazine in patients with metastatic melanoma</article-title>
          <source>J. Clin. Oncol.</source>
          <volume>17</volume>
          <year>1999</year>
          <fpage>2745</fpage>
          <lpage>2751</lpage>
          <pub-id pub-id-type="pmid">10561349</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0125">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chaudhary</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Munshi</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Scanning electron microscopic analysis of breast aspirates</article-title>
          <source>Cytopathology</source>
          <volume>6</volume>
          <year>1995</year>
          <fpage>162</fpage>
          <lpage>167</lpage>
          <pub-id pub-id-type="pmid">7669927</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0955">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>H.M.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>S.C.</given-names>
            </name>
          </person-group>
          <article-title>Effects of the anti-bacterial peptide cecropin B and its analogs, cecropins B-1 and B-2, on liposomes, bacteria, and cancer cells</article-title>
          <source>Biochim. Biophys. Acta</source>
          <volume>1336</volume>
          <year>1997</year>
          <fpage>171</fpage>
          <lpage>179</lpage>
          <pub-id pub-id-type="pmid">9305787</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0130">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Hong</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Underhill</surname>
              <given-names>C.B.</given-names>
            </name>
            <name>
              <surname>Creswell</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>RGD-tachyplesin inhibits tumor growth</article-title>
          <source>Cancer Res.</source>
          <volume>61</volume>
          <year>2001</year>
          <fpage>2434</fpage>
          <lpage>2438</lpage>
          <pub-id pub-id-type="pmid">11289111</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0135">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chernysh</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>S.I.</given-names>
            </name>
            <name>
              <surname>Bekker</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Pleskach</surname>
              <given-names>V.A.</given-names>
            </name>
            <name>
              <surname>Filatova</surname>
              <given-names>N.A.</given-names>
            </name>
            <name>
              <surname>Anikin</surname>
              <given-names>V.B.</given-names>
            </name>
            <name>
              <surname>Platonov</surname>
              <given-names>V.G.</given-names>
            </name>
            <name>
              <surname>Bulet</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Antiviral and antitumor peptides from insects</article-title>
          <source>Proc. Natl. Acad. Sci. U.S.A.</source>
          <volume>99</volume>
          <year>2002</year>
          <fpage>12628</fpage>
          <lpage>12632</lpage>
          <pub-id pub-id-type="pmid">12235362</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0960">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chu</surname>
              <given-names>S.T.</given-names>
            </name>
            <name>
              <surname>Cheng</surname>
              <given-names>H.H.</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>C.J.</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>H.C.</given-names>
            </name>
            <name>
              <surname>Chi</surname>
              <given-names>C.C.</given-names>
            </name>
            <name>
              <surname>Su</surname>
              <given-names>H.H.</given-names>
            </name>
            <name>
              <surname>Hsu</surname>
              <given-names>S.S.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>J.L.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>I.S.</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>S.I.</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>Y.C.</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>J.K.</given-names>
            </name>
            <name>
              <surname>Ho</surname>
              <given-names>C.M.</given-names>
            </name>
            <name>
              <surname>Jan</surname>
              <given-names>C.R.</given-names>
            </name>
          </person-group>
          <article-title>Phospholipase A2-independent Ca<sup>2+</sup> entry and subsequent apoptosis induced by melittin in human MG63 osteosarcoma cells</article-title>
          <source>Life Sci.</source>
          <volume>80</volume>
          <year>2007</year>
          <fpage>364</fpage>
          <lpage>369</lpage>
          <pub-id pub-id-type="pmid">17054998</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0140">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cichorek</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Kozlowska</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Witkowski</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Zarzeczna</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Flow cytometric estimation of the plasma membrane diversity of transplantable melanomas, using annexin V</article-title>
          <source>Folia Histochem. Cytobiol.</source>
          <volume>38</volume>
          <year>2000</year>
          <fpage>41</fpage>
          <lpage>43</lpage>
          <pub-id pub-id-type="pmid">10763124</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0145">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Connor</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Bucana</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Fidler</surname>
              <given-names>I.J.</given-names>
            </name>
            <name>
              <surname>Schroit</surname>
              <given-names>A.J.</given-names>
            </name>
          </person-group>
          <article-title>Differentiation-dependent expression of phosphatidylserine in mammalian plasma membranes: quantitative assessment of outer-leaflet lipid by prothrombinase complex formation</article-title>
          <source>Proc. Natl. Acad. Sci. U.S.A.</source>
          <volume>86</volume>
          <year>1989</year>
          <fpage>3184</fpage>
          <lpage>3188</lpage>
          <pub-id pub-id-type="pmid">2717615</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0150">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cruciani</surname>
              <given-names>R.A.</given-names>
            </name>
            <name>
              <surname>Barker</surname>
              <given-names>J.L.</given-names>
            </name>
            <name>
              <surname>Zasloff</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>H.C.</given-names>
            </name>
            <name>
              <surname>Colamonici</surname>
              <given-names>O.</given-names>
            </name>
          </person-group>
          <article-title>Antibiotic magainins exert cytolytic activity against transformed cell lines through channel formation</article-title>
          <source>Proc. Natl. Acad. Sci. U.S.A.</source>
          <volume>88</volume>
          <year>1991</year>
          <fpage>3792</fpage>
          <lpage>3796</lpage>
          <pub-id pub-id-type="pmid">1708887</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0155">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Davis</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Jang</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Middleton</surname>
              <given-names>K.M.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Weisz</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Ling</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Bekesi</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Novel suicide ligands of tubulin arrest cancer cells in S-phase</article-title>
          <source>Neoplasia</source>
          <volume>1</volume>
          <year>1999</year>
          <fpage>498</fpage>
          <lpage>507</lpage>
          <pub-id pub-id-type="pmid">10935497</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0160">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dennison</surname>
              <given-names>S.R.</given-names>
            </name>
            <name>
              <surname>Whittaker</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Harris</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Phoenix</surname>
              <given-names>D.A.</given-names>
            </name>
          </person-group>
          <article-title>Anticancer alpha-helical peptides and structure/function relationships underpinning their interactions with tumour cell membranes</article-title>
          <source>Curr. Protein Pept. Sci.</source>
          <volume>7</volume>
          <year>2006</year>
          <fpage>487</fpage>
          <lpage>499</lpage>
          <pub-id pub-id-type="pmid">17168782</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0165">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dennison</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Harris</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Bhatt</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Singh</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Phoenix</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>A theoretical analysis of secondary structural characteristics of anticancer peptides</article-title>
          <source>Mol. Cell. Biochem.</source>
          <volume>333</volume>
          <year>2010</year>
          <fpage>129</fpage>
          <lpage>135</lpage>
          <pub-id pub-id-type="pmid">19629645</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0170">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dobrzynska</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Kotynska</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Figaszewski</surname>
              <given-names>Z.</given-names>
            </name>
          </person-group>
          <article-title>Changes in electrical charge of phosphatidylcholine and phosphatidylserine liposomal membranes caused by adsorption of monovalent ions</article-title>
          <source>Chem Analityczna</source>
          <volume>52</volume>
          <year>2007</year>
          <fpage>931</fpage>
          <lpage>944</lpage>
        </element-citation>
      </ref>
      <ref id="bib0175">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Domagala</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Koss</surname>
              <given-names>L.G.</given-names>
            </name>
          </person-group>
          <article-title>Surface configuration of human tumor cells obtained by fine needle aspiration biopsy</article-title>
          <source>Scan. Electron. Micros.</source>
          <volume>3</volume>
          <year>1980</year>
          <fpage>101</fpage>
          <lpage>108</lpage>
        </element-citation>
      </ref>
      <ref id="bib0965">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Doyle</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Brinkworth</surname>
              <given-names>C.S.</given-names>
            </name>
            <name>
              <surname>Wegener</surname>
              <given-names>K.L.</given-names>
            </name>
            <name>
              <surname>Carver</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Llewellyn</surname>
              <given-names>L.E.</given-names>
            </name>
            <name>
              <surname>Olver</surname>
              <given-names>I.N.</given-names>
            </name>
            <name>
              <surname>Bowie</surname>
              <given-names>J.H.</given-names>
            </name>
            <name>
              <surname>Wabnitz</surname>
              <given-names>P.A.</given-names>
            </name>
            <name>
              <surname>Tyler</surname>
              <given-names>M.J.</given-names>
            </name>
          </person-group>
          <article-title>nNOS inhibition, antimicrobial and anticancer activity of the amphibian skin peptide, citropin 1.1 and synthetic modifications. The solution structure of a modified citropin 1.1</article-title>
          <source>Eur. J. Biochem.</source>
          <volume>270</volume>
          <year>2003</year>
          <fpage>1141</fpage>
          <lpage>1153</lpage>
          <pub-id pub-id-type="pmid">12631273</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0970">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Drechsler</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Andrä</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Online monitoring of metabolism and morphology of peptide-treated neuroblastoma cancer cells and keratinocytes</article-title>
          <source>J. Bioenerg. Biomembr.</source>
          <volume>43</volume>
          <year>2011</year>
          <fpage>275</fpage>
          <lpage>285</lpage>
          <pub-id pub-id-type="pmid">21643697</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0180">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dredge</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Marriott</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Todryk</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Dalgleish</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy</article-title>
          <source>Cancer Immunol. Immunother.</source>
          <volume>51</volume>
          <year>2002</year>
          <fpage>521</fpage>
          <lpage>531</lpage>
          <pub-id pub-id-type="pmid">12384803</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0185">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Easton</surname>
              <given-names>D.M.</given-names>
            </name>
            <name>
              <surname>Nijnik</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Mayer</surname>
              <given-names>M.L.</given-names>
            </name>
            <name>
              <surname>Hancock</surname>
              <given-names>R.E.W.</given-names>
            </name>
          </person-group>
          <article-title>Potential of immunomodulatory host defense peptides as novel anti-infectives</article-title>
          <source>Trends Biotechnol.</source>
          <volume>27</volume>
          <year>2009</year>
          <fpage>582</fpage>
          <lpage>590</lpage>
          <pub-id pub-id-type="pmid">19683819</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0190">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ebbinghaus</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Hersh</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Cunningham</surname>
              <given-names>C.C.</given-names>
            </name>
            <name>
              <surname>O’Day</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>McDermott</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Stephenson</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Richards</surname>
              <given-names>D.A.</given-names>
            </name>
            <name>
              <surname>Eckardt</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Haider</surname>
              <given-names>O.L.</given-names>
            </name>
            <name>
              <surname>Hammon</surname>
              <given-names>L.A.</given-names>
            </name>
          </person-group>
          <article-title>Phase II study of synthadotin (SYN-D; ILX651) administered daily for 5 consecutive days once every 3 weeks (qdx5q3w) in patients (Pts) with inoperable locally advanced or metastatic melanoma</article-title>
          <source>J. Clin. Oncol.</source>
          <volume>22</volume>
          <issue>suppl.</issue>
          <year>2004</year>
          <fpage>7530</fpage>
        </element-citation>
      </ref>
      <ref id="bib0975">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Eliassen</surname>
              <given-names>L.T.</given-names>
            </name>
            <name>
              <surname>Haug</surname>
              <given-names>B.E.</given-names>
            </name>
            <name>
              <surname>Berge</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Rekdal</surname>
              <given-names>O.</given-names>
            </name>
          </person-group>
          <article-title>Enhanced antitumour activity of 15-residue bovine lactoferricin derivatives containing bulky aromatic amino acids and lipophilic N-terminal modifications</article-title>
          <source>J Pept. Sci.</source>
          <volume>9</volume>
          <year>2003</year>
          <fpage>510</fpage>
          <lpage>517</lpage>
          <pub-id pub-id-type="pmid">12952392</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0195">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Eliassen</surname>
              <given-names>L.T.</given-names>
            </name>
            <name>
              <surname>Berge</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Leknessund</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Wikman</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Lindin</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Lokke</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Ponthan</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Johnsen</surname>
              <given-names>J.I.</given-names>
            </name>
            <name>
              <surname>Sveinbjornsson</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Kogner</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Flaegstad</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Rekdal</surname>
              <given-names>O.</given-names>
            </name>
          </person-group>
          <article-title>The antimicrobial peptide, lactoferricin B, is cytotoxic to neuroblastoma cells in vitro and inhibits xenograft growth in vivo</article-title>
          <source>Int. J. Cancer</source>
          <volume>119</volume>
          <year>2006</year>
          <fpage>493</fpage>
          <lpage>500</lpage>
          <pub-id pub-id-type="pmid">16572423</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0200">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Eliassen</surname>
              <given-names>L.T.</given-names>
            </name>
            <name>
              <surname>Berge</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Sveinbjornsson</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Svendsen</surname>
              <given-names>J.S.</given-names>
            </name>
            <name>
              <surname>Vorland</surname>
              <given-names>L.H.</given-names>
            </name>
            <name>
              <surname>Rekdal</surname>
              <given-names>O.</given-names>
            </name>
          </person-group>
          <article-title>Evidence for a direct antitumor mechanism of action of bovine lactoferricin</article-title>
          <source>Anticancer Res.</source>
          <volume>22</volume>
          <year>2002</year>
          <fpage>2703</fpage>
          <lpage>2710</lpage>
          <pub-id pub-id-type="pmid">12529985</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0205">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Epand</surname>
              <given-names>R.M.</given-names>
            </name>
            <name>
              <surname>Epand</surname>
              <given-names>R.F.</given-names>
            </name>
            <name>
              <surname>Arnusch</surname>
              <given-names>C.J.</given-names>
            </name>
            <name>
              <surname>Papahadjopoulos-Sternberg</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Shai</surname>
              <given-names>Y.</given-names>
            </name>
          </person-group>
          <article-title>Lipid clustering by three homologous arginine-rich antimicrobial peptides is insensitive to amino acid arrangement and induced secondary structure</article-title>
          <source>Biochim. Biophys. Acta</source>
          <volume>1798</volume>
          <year>2010</year>
          <fpage>1272</fpage>
          <lpage>1280</lpage>
          <pub-id pub-id-type="pmid">20302840</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0210">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Epand</surname>
              <given-names>R.M.</given-names>
            </name>
            <name>
              <surname>Epand</surname>
              <given-names>R.F.</given-names>
            </name>
          </person-group>
          <article-title>Lipid domains in bacterial membranes and the action of antimicrobial agents</article-title>
          <source>Biochim. Biophys. Acta</source>
          <volume>1788</volume>
          <year>2009</year>
          <fpage>289</fpage>
          <lpage>294</lpage>
          <pub-id pub-id-type="pmid">18822270</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0215">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Epand</surname>
              <given-names>R.M.</given-names>
            </name>
            <name>
              <surname>Epand</surname>
              <given-names>R.F.</given-names>
            </name>
          </person-group>
          <article-title>Bacterial membrane lipids in the action of antimicrobial agents</article-title>
          <source>J. Pept. Sci.</source>
          <volume>17</volume>
          <year>2011</year>
          <fpage>298</fpage>
          <lpage>305</lpage>
          <pub-id pub-id-type="pmid">21480436</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0220">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Espinosa</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Zamora</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Feliu</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>González Barón</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Classification of anticancer drugs – a new system based on therapeutic targets</article-title>
          <source>Cancer Treat. Rev.</source>
          <volume>29</volume>
          <year>2003</year>
          <fpage>515</fpage>
          <lpage>523</lpage>
          <pub-id pub-id-type="pmid">14585261</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0225">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fadnes</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Rekdal</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Uhlin-Hansen</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>The anticancer activity of lytic peptides is inhibited by heparan sulfate on the surface of the tumor cells</article-title>
          <source>BMC Cancer</source>
          <volume>9</volume>
          <year>2009</year>
          <fpage>183</fpage>
          <pub-id pub-id-type="pmid">19527490</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0230">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fadnes</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Uhlin-Hansen</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Lindin</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Rekdal</surname>
              <given-names>O.</given-names>
            </name>
          </person-group>
          <article-title>Small lytic peptides escape the inhibitory effect of heparan sulfate on the surface of cancer cells</article-title>
          <source>BMC Cancer</source>
          <volume>11</volume>
          <year>2011</year>
          <fpage>116</fpage>
          <pub-id pub-id-type="pmid">21453492</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0235">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fadok</surname>
              <given-names>V.A.</given-names>
            </name>
            <name>
              <surname>Voelker</surname>
              <given-names>D.R.</given-names>
            </name>
            <name>
              <surname>Campbell</surname>
              <given-names>P.A.</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>J.J.</given-names>
            </name>
            <name>
              <surname>Bratton</surname>
              <given-names>D.L.</given-names>
            </name>
            <name>
              <surname>Henson</surname>
              <given-names>P.M.</given-names>
            </name>
          </person-group>
          <article-title>Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages</article-title>
          <source>J. Immunol.</source>
          <volume>148</volume>
          <year>1992</year>
          <fpage>2207</fpage>
          <lpage>2216</lpage>
          <pub-id pub-id-type="pmid">1545126</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0240">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Furlong</surname>
              <given-names>S.J.</given-names>
            </name>
            <name>
              <surname>Mader</surname>
              <given-names>J.S.</given-names>
            </name>
            <name>
              <surname>Hoskin</surname>
              <given-names>D.W.</given-names>
            </name>
          </person-group>
          <article-title>Bovine lactoferricin induces caspase-independent apoptosis in human B-lymphoma cells and extends the survival of immune-deficient mice bearing B-lymphoma xenografts</article-title>
          <source>Exp. Mol. Pathol.</source>
          <volume>88</volume>
          <year>2010</year>
          <fpage>371</fpage>
          <lpage>375</lpage>
          <pub-id pub-id-type="pmid">20171209</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0245">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gifford</surname>
              <given-names>J.L.</given-names>
            </name>
            <name>
              <surname>Hunter</surname>
              <given-names>H.N.</given-names>
            </name>
            <name>
              <surname>Vogel</surname>
              <given-names>H.J.</given-names>
            </name>
          </person-group>
          <article-title>Lactoferricin: a lactoferrin-derived peptide with antimicrobial, antiviral, antitumor and immunological properties</article-title>
          <source>Cell. Mol. Life Sci.</source>
          <volume>62</volume>
          <year>2005</year>
          <fpage>2588</fpage>
          <lpage>2598</lpage>
          <pub-id pub-id-type="pmid">16261252</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0250">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gillet</surname>
              <given-names>J.P.</given-names>
            </name>
            <name>
              <surname>Gottesman</surname>
              <given-names>M.M.</given-names>
            </name>
          </person-group>
          <article-title>Mechanisms of multidrug resistance in cancer</article-title>
          <source>Methods Mol. Biol.</source>
          <volume>596</volume>
          <year>2010</year>
          <fpage>47</fpage>
          <lpage>76</lpage>
          <pub-id pub-id-type="pmid">19949920</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0255">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gottesman</surname>
              <given-names>M.M.</given-names>
            </name>
          </person-group>
          <article-title>Mechanisms of cancer drug resistance</article-title>
          <source>Annu. Rev. Med.</source>
          <volume>53</volume>
          <year>2002</year>
          <fpage>615</fpage>
          <lpage>627</lpage>
          <pub-id pub-id-type="pmid">11818492</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0260">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gregory</surname>
              <given-names>S.M.</given-names>
            </name>
            <name>
              <surname>Cavenaugh</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Journigan</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Pokorny</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Almeida</surname>
              <given-names>P.F.F.</given-names>
            </name>
          </person-group>
          <article-title>A quantitative model for the all-or-none permeabilization of phospholipid vesicles by the antimicrobial peptide Cecropin A</article-title>
          <source>Biophys. J.</source>
          <volume>94</volume>
          <year>2008</year>
          <fpage>1667</fpage>
          <lpage>1680</lpage>
          <pub-id pub-id-type="pmid">17921201</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0265">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Griffiths</surname>
              <given-names>J.R.</given-names>
            </name>
          </person-group>
          <article-title>Are cancer cells acidic?</article-title>
          <source>Br. J. Cancer</source>
          <volume>64</volume>
          <year>1991</year>
          <fpage>425</fpage>
          <lpage>427</lpage>
          <pub-id pub-id-type="pmid">1911181</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0270">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Habermann</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Jentsch</surname>
              <given-names>T.J.</given-names>
            </name>
          </person-group>
          <article-title>Sequenzanalyse des Melttins aus den tryptischen und peptischen Spaltsstücken des Bienengiftes, Hoppe Seylers</article-title>
          <source>Z. Physiol. Chem.</source>
          <volume>348</volume>
          <year>1967</year>
          <fpage>37</fpage>
          <lpage>50</lpage>
          <pub-id pub-id-type="pmid">5592400</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0275">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hancock</surname>
              <given-names>R.E.W.</given-names>
            </name>
            <name>
              <surname>Sahl</surname>
              <given-names>H.G.</given-names>
            </name>
          </person-group>
          <article-title>Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies</article-title>
          <source>Nat. Biotechnol.</source>
          <volume>24</volume>
          <year>2006</year>
          <fpage>1551</fpage>
          <lpage>1557</lpage>
          <pub-id pub-id-type="pmid">17160061</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0280">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Helmbach</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Rossmann</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Kern</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Schadendorf</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Drug-resistance in human melanoma</article-title>
          <source>Int. J. Cancer</source>
          <volume>93</volume>
          <year>2001</year>
          <fpage>617</fpage>
          <lpage>622</lpage>
          <pub-id pub-id-type="pmid">11477569</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0285">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hickel</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Danner-Pongratz</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Amenitsch</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Degovics</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Rappolt</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Lohner</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Pabst</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Influence of antimicrobial peptides on the formation of nonlamellar lipid mesophases</article-title>
          <source>Biochim. Biophys. Acta</source>
          <volume>1778</volume>
          <year>2008</year>
          <fpage>2325</fpage>
          <lpage>2333</lpage>
          <pub-id pub-id-type="pmid">18582435</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0290">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Holle</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Song</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Holle</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Wei</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Wagner</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>X.</given-names>
            </name>
          </person-group>
          <article-title>A matrix metalloproteinase 2 cleavable melittin/avidin conjugate specifically targets tumor cells in vitro and in vivo</article-title>
          <source>Int. J. Oncol.</source>
          <volume>22</volume>
          <year>2003</year>
          <fpage>93</fpage>
          <lpage>98</lpage>
          <pub-id pub-id-type="pmid">12469190</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0295">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hoskin</surname>
              <given-names>D.W.</given-names>
            </name>
            <name>
              <surname>Ramamoorthy</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Studies on anticancer activities of antimicrobial peptides</article-title>
          <source>Biochim. Biophys. Acta</source>
          <volume>1778</volume>
          <year>2008</year>
          <fpage>357</fpage>
          <lpage>375</lpage>
          <pub-id pub-id-type="pmid">18078805</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0300">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hristova</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Selsted</surname>
              <given-names>M.E.</given-names>
            </name>
            <name>
              <surname>White</surname>
              <given-names>S.H.</given-names>
            </name>
          </person-group>
          <article-title>Critical role of lipid composition in membrane permeabilization by rabbit neutrophil defensins</article-title>
          <source>J. Biol. Chem.</source>
          <volume>272</volume>
          <year>1997</year>
          <fpage>24224</fpage>
          <lpage>24233</lpage>
          <pub-id pub-id-type="pmid">9305875</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0305">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Huang</surname>
              <given-names>H.W.</given-names>
            </name>
          </person-group>
          <article-title>Molecular mechanism of antimicrobial peptides: the origin of cooperativity</article-title>
          <source>Biochim. Biophys. Acta</source>
          <volume>1758</volume>
          <year>2006</year>
          <fpage>1292</fpage>
          <lpage>1302</lpage>
          <pub-id pub-id-type="pmid">16542637</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0310">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hunt</surname>
              <given-names>J.F.</given-names>
            </name>
            <name>
              <surname>Rath</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Rothschild</surname>
              <given-names>K.J.</given-names>
            </name>
            <name>
              <surname>Engelman</surname>
              <given-names>D.M.</given-names>
            </name>
          </person-group>
          <article-title>Spontaneous, pH-dependent membrane insertion of a transbilayer alpha-helix</article-title>
          <source>Biochemistry</source>
          <volume>36</volume>
          <year>1997</year>
          <fpage>15177</fpage>
          <lpage>15192</lpage>
          <pub-id pub-id-type="pmid">9398245</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0315">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Israelachvili</surname>
              <given-names>J.N</given-names>
            </name>
            <name>
              <surname>Marcelja</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Horn</surname>
              <given-names>R.G.</given-names>
            </name>
          </person-group>
          <article-title>Physical principles of membrane organization</article-title>
          <source>Q. Rev. Biophys.</source>
          <volume>13</volume>
          <year>1980</year>
          <fpage>121</fpage>
          <lpage>200</lpage>
          <pub-id pub-id-type="pmid">7015403</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0320">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Iwasaki</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Ishibashi</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Tanaka</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Sato</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Asaoka</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Yamakawa</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Selective cancer cell cytotoxicity of enantiomeric 9-mer peptides derived from beetle defensins depends on negatively charged phosphatidylserine on the cell surface</article-title>
          <source>Peptides</source>
          <volume>30</volume>
          <year>2009</year>
          <fpage>660</fpage>
          <lpage>668</lpage>
          <pub-id pub-id-type="pmid">19154767</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0325">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jackson</surname>
              <given-names>K.L.</given-names>
            </name>
            <name>
              <surname>Henderson</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Phillips</surname>
              <given-names>A.J.</given-names>
            </name>
          </person-group>
          <article-title>The halichondrins and E7389</article-title>
          <source>Chem. Rev.</source>
          <volume>109</volume>
          <year>2009</year>
          <fpage>3044</fpage>
          <lpage>3079</lpage>
          <pub-id pub-id-type="pmid">19534494</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0330">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jayson</surname>
              <given-names>G.C.</given-names>
            </name>
            <name>
              <surname>Lyon</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Paraskeva</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Turnbull</surname>
              <given-names>J.E.</given-names>
            </name>
            <name>
              <surname>Deakin</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Gallagher</surname>
              <given-names>J.T.</given-names>
            </name>
          </person-group>
          <article-title>Heparan sulfate undergoes specific structural changes during the progression from human colon adenoma to carcinoma in vitro</article-title>
          <source>J. Biol. Chem.</source>
          <volume>273</volume>
          <year>1998</year>
          <fpage>51</fpage>
          <lpage>57</lpage>
          <pub-id pub-id-type="pmid">9417046</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0335">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Joanne</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Nicolas</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>El Amri</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Antimicrobial peptides and viral fusion peptides: how different they are?</article-title>
          <source>Protein Pept. Lett.</source>
          <volume>16</volume>
          <year>2009</year>
          <fpage>743</fpage>
          <lpage>750</lpage>
          <pub-id pub-id-type="pmid">19601903</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0340">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kalyanaraman</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Joseph</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Kalivendi</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Konorev</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Kotamraju</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Doxorubicin-induced apoptosis: implications in cardiotoxicity</article-title>
          <source>Mol. Cell. Biochem.</source>
          <volume>234–235</volume>
          <year>2002</year>
          <fpage>119</fpage>
          <lpage>124</lpage>
        </element-citation>
      </ref>
      <ref id="bib0345">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Katsu</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Nakao</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Iwanaga</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Mode of action of an antimicrobial peptide, tachyplesin I, on biomembranes</article-title>
          <source>Biol. Pharm. Bull.</source>
          <volume>16</volume>
          <year>1993</year>
          <fpage>178</fpage>
          <lpage>181</lpage>
          <pub-id pub-id-type="pmid">7689887</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0980">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>S.S.</given-names>
            </name>
            <name>
              <surname>Bang</surname>
              <given-names>Y.J.</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>S.J.</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>B.J.</given-names>
            </name>
          </person-group>
          <article-title>In vitro activities of native and designed peptide antibiotics against drug sensitive and resistant tumor cell lines</article-title>
          <source>Peptides</source>
          <volume>24</volume>
          <year>2003</year>
          <fpage>945</fpage>
          <lpage>953</lpage>
          <pub-id pub-id-type="pmid">14499271</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0350">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kirszberg</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Lima</surname>
              <given-names>L.G.</given-names>
            </name>
            <name>
              <surname>Da Silva</surname>
              <given-names>d.O.</given-names>
            </name>
            <name>
              <surname>Pickering</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Gray</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Barrowcliffe</surname>
              <given-names>T.W.</given-names>
            </name>
            <name>
              <surname>Rumjanek</surname>
              <given-names>V.M.</given-names>
            </name>
            <name>
              <surname>Monteiro</surname>
              <given-names>R.Q.</given-names>
            </name>
          </person-group>
          <article-title>Simultaneous tissue factor expression and phosphatidylserine exposure account for the highly procoagulant pattern of melanoma cell lines</article-title>
          <source>Melanoma Res.</source>
          <volume>19</volume>
          <year>2009</year>
          <fpage>301</fpage>
          <lpage>308</lpage>
          <pub-id pub-id-type="pmid">19550359</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0355">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kjellen</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Lindahl</surname>
              <given-names>U.</given-names>
            </name>
          </person-group>
          <article-title>Proteoglycans: structures and interactions</article-title>
          <source>Annu. Rev. Biochem.</source>
          <volume>60</volume>
          <year>1991</year>
          <fpage>443</fpage>
          <lpage>475</lpage>
          <pub-id pub-id-type="pmid">1883201</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0360">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kleeff</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Ishiwata</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Kumbasar</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Friess</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Büchler</surname>
              <given-names>M.W.</given-names>
            </name>
            <name>
              <surname>Lander</surname>
              <given-names>A.D.</given-names>
            </name>
            <name>
              <surname>Korc</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer</article-title>
          <source>J. Clin. Invest.</source>
          <volume>102</volume>
          <year>1998</year>
          <fpage>1662</fpage>
          <lpage>1673</lpage>
          <pub-id pub-id-type="pmid">9802880</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0985">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Koszalka</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Kamysz</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Wejda</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Kamysz</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Bigda</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Antitumor activity of antimicrobial peptides against U937 histiocytic cell line</article-title>
          <source>Acta Biochimica Polonica</source>
          <volume>58</volume>
          <year>2011</year>
          <fpage>111</fpage>
          <lpage>117</lpage>
          <pub-id pub-id-type="pmid">21403917</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0365">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kufe</surname>
              <given-names>D.W.</given-names>
            </name>
          </person-group>
          <article-title>Mucins in cancer: function, prognosis and therapy</article-title>
          <source>Nat. Rev. Cancer</source>
          <volume>9</volume>
          <year>2009</year>
          <fpage>874</fpage>
          <lpage>885</lpage>
          <pub-id pub-id-type="pmid">19935676</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0990">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lehmann</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Retz</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Sidhu</surname>
              <given-names>S.S.</given-names>
            </name>
            <name>
              <surname>Suttmann</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Sell</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Paulsen</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Harder</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Unteregger</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Stockle</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Antitumor activity of the antimicrobial peptide magainin II against bladder cancer cell lines</article-title>
          <source>Eur. Urol.</source>
          <volume>50</volume>
          <year>2006</year>
          <fpage>141</fpage>
          <lpage>147</lpage>
          <pub-id pub-id-type="pmid">16476519</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0995">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Hahm</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Lim</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Seo</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Functional and structural characteristics of anticancer peptide Pep27 analogues</article-title>
          <source>Cancer Cell Int.</source>
          <volume>5</volume>
          <year>2005</year>
          <fpage>21</fpage>
          <lpage>34</lpage>
          <pub-id pub-id-type="pmid">16004618</pub-id>
        </element-citation>
      </ref>
      <ref id="bib1000">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>H.S.</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>C.B.</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Jang</surname>
              <given-names>S.A.</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>I.Y.</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>M.S.</given-names>
            </name>
            <name>
              <surname>Cho</surname>
              <given-names>J.H.</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>S.C.</given-names>
            </name>
          </person-group>
          <article-title>Mechanism of anticancer activity of buforin IIb, a histone H2A-derived peptide</article-title>
          <source>Cancer Lett.</source>
          <volume>271</volume>
          <year>2008</year>
          <fpage>47</fpage>
          <lpage>55</lpage>
          <pub-id pub-id-type="pmid">18617323</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0370">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Leuschner</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Hansel</surname>
              <given-names>W.</given-names>
            </name>
          </person-group>
          <article-title>Membrane disrupting lytic peptides for cancer treatments</article-title>
          <source>Curr. Pharm. Des.</source>
          <volume>10</volume>
          <year>2004</year>
          <fpage>2299</fpage>
          <lpage>2310</lpage>
          <pub-id pub-id-type="pmid">15279610</pub-id>
        </element-citation>
      </ref>
      <ref id="bib1005">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>Q.</given-names>
            </name>
            <name>
              <surname>Ouyang</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Peng</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Hong</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Effects of tachyplesin on the regulation of cell cycle in human hepatocarcinoma SMMC-7721 cells</article-title>
          <source>World J. Gastroenterol.</source>
          <volume>9</volume>
          <year>2003</year>
          <fpage>454</fpage>
          <lpage>458</lpage>
          <pub-id pub-id-type="pmid">12632496</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0375">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>Y.C.</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Ye</surname>
              <given-names>S.K.</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>C.W.</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>Y.N.</given-names>
            </name>
          </person-group>
          <article-title>Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents</article-title>
          <source>Am. J. Pathol.</source>
          <volume>168</volume>
          <year>2006</year>
          <fpage>1107</fpage>
          <lpage>1118</lpage>
          <pub-id pub-id-type="pmid">16565487</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0380">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liebersbach</surname>
              <given-names>B.F.</given-names>
            </name>
            <name>
              <surname>Sanderson</surname>
              <given-names>R.D.</given-names>
            </name>
          </person-group>
          <article-title>Expression of syndecan-1 inhibits cell invasion into type I collagen</article-title>
          <source>J. Biol. Chem.</source>
          <volume>269</volume>
          <year>1994</year>
          <fpage>20013</fpage>
          <lpage>20019</lpage>
          <pub-id pub-id-type="pmid">8051085</pub-id>
        </element-citation>
      </ref>
      <ref id="bib1010">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lin</surname>
              <given-names>W.J.</given-names>
            </name>
            <name>
              <surname>Chien</surname>
              <given-names>Y.L.</given-names>
            </name>
            <name>
              <surname>Pan</surname>
              <given-names>C.Y.</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>T.L.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>J.Y.</given-names>
            </name>
            <name>
              <surname>Chiu</surname>
              <given-names>S.J.</given-names>
            </name>
            <name>
              <surname>Hui</surname>
              <given-names>C.F.</given-names>
            </name>
          </person-group>
          <article-title>Epinecidin-1, an antimicrobial peptide from fish (Epinephelus coioides) which has an antitumor effect like lytic peptides in human fibrosarcoma cells</article-title>
          <source>Peptides</source>
          <volume>30</volume>
          <year>2009</year>
          <fpage>283</fpage>
          <lpage>290</lpage>
          <pub-id pub-id-type="pmid">19007829</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0385">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Litynska</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Przybylo</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Pochec</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Hoja-Lukowicz</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Ciolczyk</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Laidler</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Gil</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Comparison of the lectin-binding pattern in different human melanoma cell lines</article-title>
          <source>Melanoma Res.</source>
          <volume>11</volume>
          <year>2001</year>
          <fpage>205</fpage>
          <lpage>212</lpage>
          <pub-id pub-id-type="pmid">11468508</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0390">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Lohner</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <chapter-title>The role of membrane lipid composition in cell targeting of antimicrobial peptides</chapter-title>
          <person-group person-group-type="editor">
            <name>
              <surname>Lohner</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <source>Development of Novel Antimicrobial Agents: Emerging Strategies</source>
          <year>2001</year>
          <publisher-name>Horizon Scientific Press</publisher-name>
          <publisher-loc>Wymondham, Norfolk, U.K.</publisher-loc>
          <fpage>149</fpage>
          <lpage>165</lpage>
        </element-citation>
      </ref>
      <ref id="bib0395">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lohner</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>New strategies for novel antibiotics: peptides targeting bacterial cell membranes</article-title>
          <source>Gen. Physiol. Biophys.</source>
          <volume>28</volume>
          <year>2009</year>
          <fpage>105</fpage>
          <lpage>116</lpage>
          <pub-id pub-id-type="pmid">19592707</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0400">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lohner</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Blondelle</surname>
              <given-names>S.E.</given-names>
            </name>
          </person-group>
          <article-title>Molecular mechanisms of membrane perturbation by antimicrobial peptides and the use of biophysical studies in the design of novel peptide antibiotics</article-title>
          <source>Comb. Chem. High Throughput Screen.</source>
          <volume>8</volume>
          <year>2005</year>
          <fpage>241</fpage>
          <lpage>256</lpage>
          <pub-id pub-id-type="pmid">15892626</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0405">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lohner</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Latal</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Lehrer</surname>
              <given-names>R.I.</given-names>
            </name>
            <name>
              <surname>Ganz</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Differential scanning microcalorimetry indicates that human defensin, HNP-2, interacts specifically with biomembrane mimetic systems</article-title>
          <source>Biochemistry</source>
          <volume>36</volume>
          <year>1997</year>
          <fpage>1525</fpage>
          <lpage>1531</lpage>
          <pub-id pub-id-type="pmid">9063901</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0410">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lohner</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Prenner</surname>
              <given-names>E.J.</given-names>
            </name>
          </person-group>
          <article-title>Differential scanning calorimetry and X-ray diffraction studies of the specificity of the interaction of antimicrobial peptides with membrane-mimetic systems</article-title>
          <source>Biochim. Biophys. Acta</source>
          <volume>1462</volume>
          <year>1999</year>
          <fpage>141</fpage>
          <lpage>156</lpage>
          <pub-id pub-id-type="pmid">10590306</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0415">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ludtke</surname>
              <given-names>S.J.</given-names>
            </name>
            <name>
              <surname>He</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Heller</surname>
              <given-names>W.T.</given-names>
            </name>
            <name>
              <surname>Harroun</surname>
              <given-names>T.A.</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>H.W.</given-names>
            </name>
          </person-group>
          <article-title>Membrane pores induced by magainin</article-title>
          <source>Biochemistry</source>
          <volume>35</volume>
          <year>1996</year>
          <fpage>13723</fpage>
          <lpage>13728</lpage>
          <pub-id pub-id-type="pmid">8901513</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0420">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mader</surname>
              <given-names>J.S.</given-names>
            </name>
            <name>
              <surname>Hoskin</surname>
              <given-names>D.W.</given-names>
            </name>
          </person-group>
          <article-title>Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment</article-title>
          <source>Expert Opin. Investig. Drugs</source>
          <volume>15</volume>
          <year>2006</year>
          <fpage>933</fpage>
          <lpage>946</lpage>
        </element-citation>
      </ref>
      <ref id="bib0425">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mader</surname>
              <given-names>J.S.</given-names>
            </name>
            <name>
              <surname>Salsman</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Conrad</surname>
              <given-names>D.M.</given-names>
            </name>
            <name>
              <surname>Hoskin</surname>
              <given-names>D.W.</given-names>
            </name>
          </person-group>
          <article-title>Bovine lactoferricin selectively induces apoptosis in human leukemia and carcinoma cell lines</article-title>
          <source>Mol. Cancer Ther.</source>
          <volume>4</volume>
          <year>2005</year>
          <fpage>612</fpage>
          <lpage>624</lpage>
          <pub-id pub-id-type="pmid">15827335</pub-id>
        </element-citation>
      </ref>
      <ref id="bib1015">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mader</surname>
              <given-names>J.S</given-names>
            </name>
            <name>
              <surname>Mookherjee</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Hancock</surname>
              <given-names>R.E.W.</given-names>
            </name>
            <name>
              <surname>Bleackley</surname>
              <given-names>R.C.</given-names>
            </name>
          </person-group>
          <article-title>The human host defense peptide LL-37 induces apoptosis in a calpain- and apoptosis-inducing factor-dependent manner involving bax activity</article-title>
          <source>Mol. Cancer Res.</source>
          <volume>7</volume>
          <year>2009</year>
          <fpage>689</fpage>
          <lpage>702</lpage>
          <pub-id pub-id-type="pmid">19435812</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0430">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Makovitzki</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Fink</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Shai</surname>
              <given-names>Y.</given-names>
            </name>
          </person-group>
          <article-title>Suppression of human solid tumor growth in mice by intratumor and systemic inoculation of histidine-rich and pH-dependent host defense-like lytic peptides</article-title>
          <source>Cancer Res.</source>
          <volume>69</volume>
          <year>2009</year>
          <fpage>3458</fpage>
          <lpage>3463</lpage>
          <pub-id pub-id-type="pmid">19351852</pub-id>
        </element-citation>
      </ref>
      <ref id="bib1020">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Manavbasi</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Gofman</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Ben Tal</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Willumeit</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Zweytick</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Lohner</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Structural aspects of the interaction of Nk-2 derived peptides with cancer cells</article-title>
          <source>Biophys. J.</source>
          <volume>98</volume>
          <year>2010</year>
          <fpage>277a</fpage>
          <pub-id pub-id-type="pmid">20338849</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0435">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mandard</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Bulet</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Caille</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Daffre</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Vovelle</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>The solution structure of gomesin, an antimicrobial cysteine-rich peptide from the spider</article-title>
          <source>Eur. J. Biochem.</source>
          <volume>269</volume>
          <year>2002</year>
          <fpage>1190</fpage>
          <lpage>1198</lpage>
          <pub-id pub-id-type="pmid">11856345</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0440">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marsh</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Lateral pressure in membranes</article-title>
          <source>Biochim. Biophys. Acta</source>
          <volume>1286</volume>
          <year>1996</year>
          <fpage>183</fpage>
          <lpage>223</lpage>
          <pub-id pub-id-type="pmid">8982283</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0445">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Martin</surname>
              <given-names>S.J.</given-names>
            </name>
            <name>
              <surname>Reutelingsperger</surname>
              <given-names>C.P.</given-names>
            </name>
            <name>
              <surname>McGahon</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Rader</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>van Schie</surname>
              <given-names>R.C.</given-names>
            </name>
            <name>
              <surname>LaFace</surname>
              <given-names>D.M.</given-names>
            </name>
            <name>
              <surname>Green</surname>
              <given-names>D.R.</given-names>
            </name>
          </person-group>
          <article-title>Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl</article-title>
          <source>J. Exp. Med.</source>
          <volume>182</volume>
          <year>1995</year>
          <fpage>1545</fpage>
          <lpage>1556</lpage>
          <pub-id pub-id-type="pmid">7595224</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0450">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Matsuda</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Maruyama</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Guo</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Kleeff</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Itakura</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Matsumoto</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Lander</surname>
              <given-names>A.D.</given-names>
            </name>
            <name>
              <surname>Korc</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells</article-title>
          <source>Cancer Res.</source>
          <volume>61</volume>
          <year>2001</year>
          <fpage>5562</fpage>
          <lpage>5569</lpage>
          <pub-id pub-id-type="pmid">11454708</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0455">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Matsuzaki</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Murase</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Fujii</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Miyajima</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>An antimicrobal peptide, Magainin 2, induced rapid flip-flop of phospholipids coupled with pore formation and peptide translocation</article-title>
          <source>Biochemistry</source>
          <volume>35</volume>
          <year>1996</year>
          <fpage>11361</fpage>
          <lpage>11368</lpage>
          <pub-id pub-id-type="pmid">8784191</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0460">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Matsuzaki</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Yoneyama</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Miyajima</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Pore formation and transition of melittin</article-title>
          <source>Biophys. J.</source>
          <volume>73</volume>
          <year>1997</year>
          <fpage>831</fpage>
          <lpage>838</lpage>
          <pub-id pub-id-type="pmid">9251799</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0465">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>May</surname>
              <given-names>G.L.</given-names>
            </name>
            <name>
              <surname>Wright</surname>
              <given-names>L.C.</given-names>
            </name>
            <name>
              <surname>Dyne</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Mackinnon</surname>
              <given-names>W.B.</given-names>
            </name>
            <name>
              <surname>Fox</surname>
              <given-names>R.M.</given-names>
            </name>
            <name>
              <surname>Mountford</surname>
              <given-names>C.E.</given-names>
            </name>
          </person-group>
          <article-title>Plasma membrane lipid composition of vinblastine sensitive and resistant human leukaemic lymphoblasts</article-title>
          <source>Int. J. Cancer</source>
          <volume>42</volume>
          <year>1988</year>
          <fpage>728</fpage>
          <lpage>733</lpage>
          <pub-id pub-id-type="pmid">3263327</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0470">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mazzoni</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Trave</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>Cytoplasmic membrane cholesterol and doxorubicin cytotoxicity in drug-sensitive and multidrug-resistant human ovarian cancer cells</article-title>
          <source>Oncol. Res.</source>
          <volume>5</volume>
          <year>1993</year>
          <fpage>75</fpage>
          <lpage>82</lpage>
          <pub-id pub-id-type="pmid">8364256</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0475">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Middleton</surname>
              <given-names>M.R.</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>S.M.</given-names>
            </name>
            <name>
              <surname>Arance</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Wood</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Thatcher</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Margison</surname>
              <given-names>G.P.</given-names>
            </name>
          </person-group>
          <article-title>O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 h schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study</article-title>
          <source>Int. J. Cancer</source>
          <volume>88</volume>
          <year>2000</year>
          <fpage>469</fpage>
          <lpage>473</lpage>
          <pub-id pub-id-type="pmid">11054678</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0480">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Miller</surname>
              <given-names>T.W.</given-names>
            </name>
            <name>
              <surname>Isenberg</surname>
              <given-names>J.S.</given-names>
            </name>
            <name>
              <surname>Roberts</surname>
              <given-names>D.D.</given-names>
            </name>
          </person-group>
          <article-title>Molecular regulation of tumor angiogenesis and perfusion via redox signaling</article-title>
          <source>Chem. Rev.</source>
          <volume>109</volume>
          <year>2009</year>
          <fpage>3099</fpage>
          <lpage>3124</lpage>
          <pub-id pub-id-type="pmid">19374334</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0485">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Miyashita</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Reed</surname>
              <given-names>J.C.</given-names>
            </name>
          </person-group>
          <article-title>Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line</article-title>
          <source>Blood</source>
          <volume>81</volume>
          <year>1993</year>
          <fpage>151</fpage>
          <lpage>157</lpage>
          <pub-id pub-id-type="pmid">8417786</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0490">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Miyazaki</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Kobayashi</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Natsume</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Gondo</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Mikami</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Sakakibara</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Tsukagoshi</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis and antitumor activity of novel dolastatin 10</article-title>
          <source>Chem. Pharm. Bull.</source>
          <volume>43</volume>
          <year>1995</year>
          <fpage>1706</fpage>
          <lpage>1718</lpage>
          <pub-id pub-id-type="pmid">8536345</pub-id>
        </element-citation>
      </ref>
      <ref id="bib1025">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moon</surname>
              <given-names>D.O.</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>S.Y.</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>Y.H.</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>N.D.</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>G.Y.</given-names>
            </name>
          </person-group>
          <article-title>Melittin induces Bcl-2 and caspase-3-dependent apoptosis through downregulation of Akt phosphorylation in human leukemic U937 cells</article-title>
          <source>Toxicon</source>
          <volume>51</volume>
          <year>2008</year>
          <fpage>112</fpage>
          <lpage>120</lpage>
          <pub-id pub-id-type="pmid">17936321</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0495">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Morgan</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Ward</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Barton</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies</article-title>
          <source>Clin. Oncol.</source>
          <volume>16</volume>
          <year>2004</year>
          <fpage>549</fpage>
          <lpage>560</lpage>
        </element-citation>
      </ref>
      <ref id="bib0500">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nabholtz</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Slamon</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>New adjuvant strategies for breast cancer: meeting the challenge of integrating chemotherapy and trastuzumab (Herceptin)</article-title>
          <source>Semin. Oncol.</source>
          <volume>28</volume>
          <year>2001</year>
          <fpage>1</fpage>
          <lpage>12</lpage>
          <pub-id pub-id-type="pmid">11301369</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0505">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nakamura</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Furunaka</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Miyata</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Tokunaga</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Muta</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Iwanaga</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Niwa</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Takao</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Shimonishi</surname>
              <given-names>Y.</given-names>
            </name>
          </person-group>
          <article-title>Tachyplesin, a class of antimicrobial peptide from the hemocytes of the horseshoe crab (<italic>Tachypleus tridentatus</italic>). Isolation and chemical structure</article-title>
          <source>J. Biol. Chem.</source>
          <volume>263</volume>
          <year>1988</year>
          <fpage>16709</fpage>
          <lpage>16713</lpage>
          <pub-id pub-id-type="pmid">3141410</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0510">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nakatsura</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Kageshita</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Ito</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Wakamatsu</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Monji</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Ikuta</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Senju</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Ono</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Nishimura</surname>
              <given-names>Y.</given-names>
            </name>
          </person-group>
          <article-title>Identification of glypican-3 as a novel tumor marker for melanoma</article-title>
          <source>Clin. Cancer Res.</source>
          <volume>10</volume>
          <year>2004</year>
          <fpage>6612</fpage>
          <lpage>6621</lpage>
          <pub-id pub-id-type="pmid">15475451</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0515">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nakazawa</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Iwaizumi</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>A role of the cancer cell membrane fluidity in the cancer metastases: an ESR study, Tohoku</article-title>
          <source>J. Exp. Med.</source>
          <volume>157</volume>
          <year>1989</year>
          <fpage>193</fpage>
          <lpage>198</lpage>
        </element-citation>
      </ref>
      <ref id="bib0520">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Newell</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Franchi</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Pouysségur</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Tannock</surname>
              <given-names>I.</given-names>
            </name>
          </person-group>
          <article-title>Studies with glycolysis-deficient cells suggest that production of lactic acid is not the only cause of tumor acidity</article-title>
          <source>Proc. Natl. Acad. Sci. U.S.A.</source>
          <volume>90</volume>
          <year>1993</year>
          <fpage>1127</fpage>
          <lpage>1131</lpage>
          <pub-id pub-id-type="pmid">8430084</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0525">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Newman</surname>
              <given-names>D.J.</given-names>
            </name>
            <name>
              <surname>Cragg</surname>
              <given-names>G.M.</given-names>
            </name>
          </person-group>
          <article-title>Natural products as sources of new drugs over the last 25 years</article-title>
          <source>J. Nat. Prod.</source>
          <volume>70</volume>
          <year>2007</year>
          <fpage>461</fpage>
          <lpage>477</lpage>
          <pub-id pub-id-type="pmid">17309302</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0530">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nguyen</surname>
              <given-names>L.T.</given-names>
            </name>
            <name>
              <surname>Schibli</surname>
              <given-names>D.J.</given-names>
            </name>
            <name>
              <surname>Vogel</surname>
              <given-names>H.J.</given-names>
            </name>
          </person-group>
          <article-title>Structural studies and model membrane interactions of two peptides derived from bovine lactoferricin</article-title>
          <source>J. Pept. Sci.</source>
          <volume>11</volume>
          <year>2005</year>
          <fpage>379</fpage>
          <lpage>389</lpage>
          <pub-id pub-id-type="pmid">15635665</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0535">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ohtake</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Fujimoto</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Ikuta</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Saito</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Ohhira</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Ono</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Kohgo</surname>
              <given-names>Y.</given-names>
            </name>
          </person-group>
          <article-title>Proline-rich antimicrobial peptide, PR-39 gene transduction altered invasive activity and actin structure in human hepatocellular carcinoma cells</article-title>
          <source>Br. J. Cancer</source>
          <volume>81</volume>
          <year>1999</year>
          <fpage>393</fpage>
          <lpage>403</lpage>
          <pub-id pub-id-type="pmid">10507762</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0540">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Onishi</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Roy</surname>
              <given-names>M.K.</given-names>
            </name>
            <name>
              <surname>Juneja</surname>
              <given-names>L.R.</given-names>
            </name>
            <name>
              <surname>Watanabe</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Tamai</surname>
              <given-names>Y.</given-names>
            </name>
          </person-group>
          <article-title>A lactoferrin-derived peptide with cationic residues concentrated in a region of its helical structure induces necrotic cell death in a leukemic cell line (HL-60)</article-title>
          <source>J. Pept. Sci.</source>
          <volume>14</volume>
          <year>2008</year>
          <fpage>1032</fpage>
          <lpage>1038</lpage>
          <pub-id pub-id-type="pmid">18425992</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0545">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ostolaza</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Bartolomé</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>de Zárate</surname>
              <given-names>I.O.</given-names>
            </name>
            <name>
              <surname>de la Cruz</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Goni</surname>
              <given-names>F.M.</given-names>
            </name>
          </person-group>
          <article-title>Release of lipid vesicle contents by the bacterial protein toxin [alpha]-haemolysin</article-title>
          <source>Biochim. Biophys. Acta</source>
          <volume>1147</volume>
          <year>1993</year>
          <fpage>81</fpage>
          <lpage>88</lpage>
          <pub-id pub-id-type="pmid">7682112</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0550">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Papo</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Braunstein</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Eshhar</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Shai</surname>
              <given-names>Y.</given-names>
            </name>
          </person-group>
          <article-title>Suppression of human prostate tumor growth in mice by a cytolytic <sc>d</sc>-, <sc>l</sc>-amino acid peptide: membrane lysis, increased necrosis, and inhibition of prostate-specific antigen secretion</article-title>
          <source>Cancer Res.</source>
          <volume>64</volume>
          <year>2004</year>
          <fpage>5779</fpage>
          <lpage>5786</lpage>
          <pub-id pub-id-type="pmid">15313920</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0555">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Papo</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Shai</surname>
              <given-names>Y.</given-names>
            </name>
          </person-group>
          <article-title>New lytic peptides based on the <sc>d</sc>,<sc>l</sc>-amphipathic helix motif preferentially kill tumor cells compared to normal cells</article-title>
          <source>Biochemistry</source>
          <volume>42</volume>
          <year>2003</year>
          <fpage>9346</fpage>
          <lpage>9354</lpage>
          <pub-id pub-id-type="pmid">12899621</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0560">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Papo</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Shai</surname>
              <given-names>Y.</given-names>
            </name>
          </person-group>
          <article-title>Host defense peptides as new weapons in cancer treatment</article-title>
          <source>Cell. Mol. Life Sci.</source>
          <volume>62</volume>
          <year>2005</year>
          <fpage>784</fpage>
          <lpage>790</lpage>
          <pub-id pub-id-type="pmid">15868403</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0565">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Papo</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Seger</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Makovitzki</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Kalchenko</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Eshhar</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Degani</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Shai</surname>
              <given-names>Y.</given-names>
            </name>
          </person-group>
          <article-title>Inhibition of tumor growth and elimination of multiple metastases in human prostate and breast xenografts by systemic inoculation of a host defense-like lytic peptide</article-title>
          <source>Cancer Res.</source>
          <volume>66</volume>
          <year>2006</year>
          <fpage>5371</fpage>
          <lpage>5378</lpage>
          <pub-id pub-id-type="pmid">16707464</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0570">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Park</surname>
              <given-names>N.G.</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Oishi</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Aoyagi</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Iwanaga</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Yamashita</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Ohno</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Conformation of tachyplesin I from <italic>Tachypleus tridentatus</italic> when interacting with lipid matrixes</article-title>
          <source>Biochemistry</source>
          <volume>31</volume>
          <year>1992</year>
          <fpage>12241</fpage>
          <lpage>12247</lpage>
          <pub-id pub-id-type="pmid">1457421</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0575">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pastan</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Kreitman</surname>
              <given-names>R.J.</given-names>
            </name>
          </person-group>
          <article-title>Immunotoxins for targeted cancer therapy</article-title>
          <source>Adv. Drug Deliv. Rev.</source>
          <volume>31</volume>
          <year>1998</year>
          <fpage>53</fpage>
          <lpage>88</lpage>
          <pub-id pub-id-type="pmid">10837618</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0580">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Peck-Miller</surname>
              <given-names>K.A.</given-names>
            </name>
            <name>
              <surname>Darveau</surname>
              <given-names>R.P.</given-names>
            </name>
            <name>
              <surname>Fell</surname>
              <given-names>H.P.</given-names>
            </name>
          </person-group>
          <article-title>Identification of serum components that inhibit the tumoricidal activity of amphiphilic alpha helical peptides</article-title>
          <source>Cancer Chemother. Pharmacol.</source>
          <volume>32</volume>
          <year>1993</year>
          <fpage>109</fpage>
          <lpage>115</lpage>
          <pub-id pub-id-type="pmid">8485805</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0585">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Perez-Tomas</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Multidrug resistance: retrospect and prospects in anti-cancer drug treatment</article-title>
          <source>Curr. Med. Chem.</source>
          <volume>13</volume>
          <year>2006</year>
          <fpage>1859</fpage>
          <lpage>1876</lpage>
          <pub-id pub-id-type="pmid">16842198</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0590">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pettit</surname>
              <given-names>G.R.</given-names>
            </name>
            <name>
              <surname>Kamano</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Herald</surname>
              <given-names>C.L.</given-names>
            </name>
            <name>
              <surname>Tuinman</surname>
              <given-names>A.A.</given-names>
            </name>
            <name>
              <surname>Boettner</surname>
              <given-names>F.E.</given-names>
            </name>
            <name>
              <surname>Kizu</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Schmidt</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Baczynskyj</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Tomer</surname>
              <given-names>K.B.</given-names>
            </name>
            <name>
              <surname>Bontems</surname>
              <given-names>R.J.</given-names>
            </name>
          </person-group>
          <article-title>The isolation and structure of a remarkable marine animal antineoplastic constituent: dolastatin 10</article-title>
          <source>J. Am. Chem. Soc.</source>
          <volume>109</volume>
          <year>1987</year>
          <fpage>6883</fpage>
          <lpage>6885</lpage>
        </element-citation>
      </ref>
      <ref id="bib0595">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pokorny</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Almeida</surname>
              <given-names>P.F.F.</given-names>
            </name>
          </person-group>
          <article-title>Kinetics of dye efflux and lipid flip-flop induced by δ-lysin in phosphatidylcholine vesicles and the mechanism of graded release by amphipathic, α-helical peptides</article-title>
          <source>Biochemistry</source>
          <volume>43</volume>
          <year>2004</year>
          <fpage>8846</fpage>
          <lpage>8857</lpage>
          <pub-id pub-id-type="pmid">15236593</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0600">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pokorny</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Kilelee</surname>
              <given-names>E.M.</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Almeida</surname>
              <given-names>P.F.F.</given-names>
            </name>
          </person-group>
          <article-title>The activity of the amphipathic peptide δ-lysin correlates with phospholipid acyl chain structure and bilayer elastic properties</article-title>
          <source>Biophys. J.</source>
          <volume>95</volume>
          <year>2008</year>
          <fpage>4748</fpage>
          <lpage>4755</lpage>
          <pub-id pub-id-type="pmid">18708459</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0605">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rabenstein</surname>
              <given-names>D.L.</given-names>
            </name>
          </person-group>
          <article-title>Heparin and heparan sulfate: structure and function</article-title>
          <source>Nat. Prod. Rep.</source>
          <volume>19</volume>
          <year>2002</year>
          <fpage>312</fpage>
          <lpage>331</lpage>
          <pub-id pub-id-type="pmid">12137280</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0610">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ran</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Downes</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Thorpe</surname>
              <given-names>P.E.</given-names>
            </name>
          </person-group>
          <article-title>Increased exposure of anionic phospholipids on the surface of tumor blood vessels</article-title>
          <source>Cancer Res.</source>
          <volume>62</volume>
          <year>2002</year>
          <fpage>6132</fpage>
          <lpage>6140</lpage>
          <pub-id pub-id-type="pmid">12414638</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0615">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rao</surname>
              <given-names>L.V.</given-names>
            </name>
            <name>
              <surname>Tait</surname>
              <given-names>J.F.</given-names>
            </name>
            <name>
              <surname>Hoang</surname>
              <given-names>A.D.</given-names>
            </name>
          </person-group>
          <article-title>Binding of annexin V to a human ovarian carcinoma cell line (OC-2008). Contrasting effects on cell surface factor VIIa/tissue factor activity and prothrombinase activity</article-title>
          <source>Thromb. Res.</source>
          <volume>67</volume>
          <year>1992</year>
          <fpage>517</fpage>
          <lpage>531</lpage>
          <pub-id pub-id-type="pmid">1448786</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0620">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rathinakumar</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Wimley</surname>
              <given-names>W.C.</given-names>
            </name>
          </person-group>
          <article-title>Biomolecular engineering by combinatorial design and high-throughput screening: small, soluble peptides that permeabilize membranes</article-title>
          <source>J. Am. Chem. Soc.</source>
          <volume>130</volume>
          <year>2008</year>
          <fpage>9849</fpage>
          <lpage>9858</lpage>
          <pub-id pub-id-type="pmid">18611015</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0625">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rathinakumar</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Wimley</surname>
              <given-names>W.C.</given-names>
            </name>
          </person-group>
          <article-title>High-throughput discovery of broad-spectrum peptide antibiotics</article-title>
          <source>FASEB J.</source>
          <volume>24</volume>
          <year>2010</year>
          <fpage>3232</fpage>
          <lpage>3238</lpage>
          <pub-id pub-id-type="pmid">20410445</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0630">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reshetnyak</surname>
              <given-names>Y.K.</given-names>
            </name>
            <name>
              <surname>Andreev</surname>
              <given-names>O.A.</given-names>
            </name>
            <name>
              <surname>Lehnert</surname>
              <given-names>U.</given-names>
            </name>
            <name>
              <surname>Engelman</surname>
              <given-names>D.M.</given-names>
            </name>
          </person-group>
          <article-title>Translocation of molecules into cells by pH-dependent insertion of a transmembrane helix</article-title>
          <source>Proc. Natl. Acad. Sci. U.S.A.</source>
          <volume>103</volume>
          <year>2006</year>
          <fpage>6460</fpage>
          <lpage>6465</lpage>
          <pub-id pub-id-type="pmid">16608910</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0635">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reshetnyak</surname>
              <given-names>Y.K.</given-names>
            </name>
            <name>
              <surname>Segala</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Andreev</surname>
              <given-names>O.A.</given-names>
            </name>
            <name>
              <surname>Engelman</surname>
              <given-names>D.M.</given-names>
            </name>
          </person-group>
          <article-title>A monomeric membrane peptide that lives in three worlds: in solution, attached to, and inserted across lipid bilayers</article-title>
          <source>Biophys. J.</source>
          <volume>93</volume>
          <year>2007</year>
          <fpage>2363</fpage>
          <lpage>2372</lpage>
          <pub-id pub-id-type="pmid">17557792</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0640">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Riedl</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Rinner</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Asslaber</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Schaider</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Walzer</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Novak</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Lohner</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Zweytick</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>In search of a novel target – phosphatidylserine exposed by non-apoptotic tumor cells and metastases of malignancies with poor treatment efficacy</article-title>
          <source>Biochim. Biophys. Acta</source>
          <volume>1808</volume>
          <year>2011</year>
          <fpage>2638</fpage>
          <lpage>2645</lpage>
          <pub-id pub-id-type="pmid">21810406</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0645">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Riedl</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Rinner</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Tumer</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Schaider</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Lohner</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Zweytick</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Targeting the cancer cell membrane specifically with human lactoferricin derivatives</article-title>
          <source>Ann. Oncol.</source>
          <volume>22</volume>
          <issue>suppl. 3</issue>
          <year>2011</year>
          <fpage>iii31</fpage>
          <lpage>iii34</lpage>
        </element-citation>
      </ref>
      <ref id="bib0650">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Risso</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Zanetti</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Gennaro</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Cytotoxicity and apoptosis mediated by two peptides of innate immunity</article-title>
          <source>Cell. Immunol.</source>
          <volume>189</volume>
          <year>1998</year>
          <fpage>107</fpage>
          <lpage>115</lpage>
          <pub-id pub-id-type="pmid">9790724</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0655">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rodrigues</surname>
              <given-names>C.M.</given-names>
            </name>
            <name>
              <surname>Sola</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Castro</surname>
              <given-names>R.E.</given-names>
            </name>
            <name>
              <surname>Laires</surname>
              <given-names>P.A.</given-names>
            </name>
            <name>
              <surname>Brites</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Moura</surname>
              <given-names>J.J.</given-names>
            </name>
          </person-group>
          <article-title>Perturbation of membrane dynamics in nerve cells as an early event during bilirubin-induced apoptosis</article-title>
          <source>J. Lipid Res.</source>
          <volume>43</volume>
          <year>2002</year>
          <fpage>885</fpage>
          <lpage>894</lpage>
          <pub-id pub-id-type="pmid">12032163</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0660">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rodrigues</surname>
              <given-names>E.G.</given-names>
            </name>
            <name>
              <surname>Dobroff</surname>
              <given-names>A.S.</given-names>
            </name>
            <name>
              <surname>Cavarsan</surname>
              <given-names>C.F.</given-names>
            </name>
            <name>
              <surname>Paschoalin</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Nimrichter</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Mortara</surname>
              <given-names>R.A.</given-names>
            </name>
            <name>
              <surname>Santos</surname>
              <given-names>E.L.</given-names>
            </name>
            <name>
              <surname>Fazio</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Miranda</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Daffre</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Travassos</surname>
              <given-names>L.R.</given-names>
            </name>
          </person-group>
          <article-title>Effective topical treatment of subcutaneous murine B16F10-Nex2 melanoma by the antimicrobial peptide gomesin</article-title>
          <source>Neoplasia</source>
          <volume>10</volume>
          <year>2008</year>
          <fpage>61</fpage>
          <lpage>68</lpage>
          <pub-id pub-id-type="pmid">18231639</pub-id>
        </element-citation>
      </ref>
      <ref id="bib1030">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rozek</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Wegener</surname>
              <given-names>K.L.</given-names>
            </name>
            <name>
              <surname>Bowie</surname>
              <given-names>J.H.</given-names>
            </name>
            <name>
              <surname>Olver</surname>
              <given-names>I.N.</given-names>
            </name>
            <name>
              <surname>Carver</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Wallace</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>Tyler</surname>
              <given-names>M.J.</given-names>
            </name>
          </person-group>
          <article-title>The antibiotic and anticancer active aurein peptides from the Australian Bell Frogs Litoria aurea and Litoria raniformis the solution structure of aurein 1.2</article-title>
          <source>Eur. J. Biochem.</source>
          <volume>267</volume>
          <year>2000</year>
          <fpage>5330</fpage>
          <lpage>5341</lpage>
          <pub-id pub-id-type="pmid">10951191</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0665">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Safaiyan</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Lindahl</surname>
              <given-names>U.</given-names>
            </name>
            <name>
              <surname>Salmivirta</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Selective reduction of 6-O-sulfation in heparan sulfate from transformed mammary epithelial cells</article-title>
          <source>Eur. J. Biochem.</source>
          <volume>252</volume>
          <year>1998</year>
          <fpage>576</fpage>
          <lpage>582</lpage>
          <pub-id pub-id-type="pmid">9546676</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0670">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sanderson</surname>
              <given-names>R.D.</given-names>
            </name>
          </person-group>
          <article-title>Heparan sulfate proteoglycans in invasion and metastasis</article-title>
          <source>Semin. Cell Dev. Biol.</source>
          <volume>12</volume>
          <year>2001</year>
          <fpage>89</fpage>
          <lpage>98</lpage>
          <pub-id pub-id-type="pmid">11292374</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0675">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schadendorf</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Worm</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Algermissen</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Kohlmus</surname>
              <given-names>C.M.</given-names>
            </name>
            <name>
              <surname>Czarnetzki</surname>
              <given-names>B.M.</given-names>
            </name>
          </person-group>
          <article-title>Chemosensitivity testing of human malignant melanoma. A retrospective analysis of clinical response and in vitro drug sensitivity</article-title>
          <source>Cancer</source>
          <volume>73</volume>
          <year>1994</year>
          <fpage>103</fpage>
          <lpage>108</lpage>
          <pub-id pub-id-type="pmid">7506115</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0680">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schröder-Borm</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Bakalova</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Andrä</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>The NK-lysin derived peptide NK-2 preferentially kills cancer cells with increased surface levels of negatively charged phosphatidylserine</article-title>
          <source>FEBS Lett.</source>
          <volume>579</volume>
          <year>2005</year>
          <fpage>6128</fpage>
          <lpage>6134</lpage>
          <pub-id pub-id-type="pmid">16269280</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0685">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schroeder</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Gardiner</surname>
              <given-names>J.M.</given-names>
            </name>
          </person-group>
          <article-title>Membrane lipids and enzymes of cultured high- and low-metastatic B16 melanoma variants</article-title>
          <source>Cancer Res.</source>
          <volume>44</volume>
          <year>1984</year>
          <fpage>3262</fpage>
          <lpage>3269</lpage>
          <pub-id pub-id-type="pmid">6146400</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0690">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schweizer</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>Cationic amphiphilic peptides with cancer-selective toxicity</article-title>
          <source>Eur. J. Pharmacol.</source>
          <volume>625</volume>
          <year>2009</year>
          <fpage>190</fpage>
          <lpage>194</lpage>
          <pub-id pub-id-type="pmid">19835863</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0695">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Seigneuret</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Devaux</surname>
              <given-names>P.F.</given-names>
            </name>
          </person-group>
          <article-title>ATP-dependent asymmetric distribution of spin-labeled phospholipids in the erythrocyte membrane: relation to shape changes</article-title>
          <source>Proc. Natl. Acad. Sci. U.S.A.</source>
          <volume>81</volume>
          <year>1984</year>
          <fpage>3751</fpage>
          <lpage>3755</lpage>
          <pub-id pub-id-type="pmid">6587389</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0700">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sevcsik</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Pabst</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Richter</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Danner</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Amenitsch</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Lohner</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Interaction of LL-37 with model membrane systems of different complexity: influence of the lipid matrix</article-title>
          <source>Biophys. J.</source>
          <volume>94</volume>
          <year>2008</year>
          <fpage>4688</fpage>
          <lpage>4699</lpage>
          <pub-id pub-id-type="pmid">18326643</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0705">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shadidi</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Sioud</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Selective targeting of cancer cells using synthetic peptides</article-title>
          <source>Drug Resist. Updat.</source>
          <volume>6</volume>
          <year>2003</year>
          <fpage>363</fpage>
          <lpage>371</lpage>
          <pub-id pub-id-type="pmid">14744500</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0710">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shai</surname>
              <given-names>Y.</given-names>
            </name>
          </person-group>
          <article-title>Mode of action of membrane active antimicrobial peptides</article-title>
          <source>Biopolymers</source>
          <volume>66</volume>
          <year>2002</year>
          <fpage>236</fpage>
          <lpage>248</lpage>
          <pub-id pub-id-type="pmid">12491537</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0715">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sharma</surname>
              <given-names>S.V.</given-names>
            </name>
          </person-group>
          <article-title>Melittin resistance: a counterselection for ras transformation</article-title>
          <source>Oncogene</source>
          <volume>7</volume>
          <year>1992</year>
          <fpage>193</fpage>
          <lpage>201</lpage>
          <pub-id pub-id-type="pmid">1549345</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0720">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sherbet</surname>
              <given-names>G.V.</given-names>
            </name>
          </person-group>
          <article-title>Membrane fluidity and cancer metastasis</article-title>
          <source>Exp. Cell Biol.</source>
          <volume>57</volume>
          <year>1989</year>
          <fpage>198</fpage>
          <lpage>205</lpage>
          <pub-id pub-id-type="pmid">2689252</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0725">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sherbet</surname>
              <given-names>G.V.</given-names>
            </name>
            <name>
              <surname>Jackson</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Temperature-dependent surface charge modulation, membrane fluidity, and metastatic ability of L51178Y lymphoma</article-title>
          <source>Anticancer Res.</source>
          <volume>6</volume>
          <year>1986</year>
          <fpage>129</fpage>
          <lpage>134</lpage>
          <pub-id pub-id-type="pmid">3954324</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0730">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shewach</surname>
              <given-names>D.S</given-names>
            </name>
            <name>
              <surname>Kuchta</surname>
              <given-names>R.D.</given-names>
            </name>
          </person-group>
          <article-title>Introduction to cancer chemotherapeutics</article-title>
          <source>Chem. Rev.</source>
          <volume>109</volume>
          <year>2009</year>
          <fpage>2859</fpage>
          <lpage>2861</lpage>
          <pub-id pub-id-type="pmid">19583428</pub-id>
        </element-citation>
      </ref>
      <ref id="bib1035">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shi</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Liang</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>Q.</given-names>
            </name>
          </person-group>
          <article-title>Effects of tachyplesin and n-sodium butyrate on proliferation and gene expression of human gastric adenocarcinoma cell line BGC-823</article-title>
          <source>World J. Gastroenterol.</source>
          <volume>12</volume>
          <year>2006</year>
          <fpage>1694</fpage>
          <lpage>1698</lpage>
          <pub-id pub-id-type="pmid">16586536</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0735">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shore</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Review of the nitrogen mustards</article-title>
          <source>Hahnemann Mon.</source>
          <volume>82</volume>
          <year>1947</year>
          <fpage>461</fpage>
          <lpage>470</lpage>
          <pub-id pub-id-type="pmid">18895700</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0740">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Silva</surname>
              <given-names>P.I.</given-names>
            </name>
            <name>
              <surname>Daffre</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Bulet</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Isolation and characterization of gomesin, an 18-residue cysteine-rich defense peptide from the spider <italic>Acanthoscurria gomesiana</italic> hemocytes with sequence similarities to horseshoe crab antimicrobial peptides of the Tachyplesin family</article-title>
          <source>J. Biol. Chem.</source>
          <volume>275</volume>
          <year>2000</year>
          <fpage>33464</fpage>
          <lpage>33470</lpage>
          <pub-id pub-id-type="pmid">10942757</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0745">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Simmons</surname>
              <given-names>T.L.</given-names>
            </name>
            <name>
              <surname>Andrianasolo</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>McPhail</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Flatt</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Gerwick</surname>
              <given-names>W.H.</given-names>
            </name>
          </person-group>
          <article-title>Marine natural products as anticancer drugs</article-title>
          <source>Mol. Cancer Ther.</source>
          <volume>4</volume>
          <year>2005</year>
          <fpage>333</fpage>
          <lpage>342</lpage>
          <pub-id pub-id-type="pmid">15713904</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0750">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Smith</surname>
              <given-names>L.L.</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Carthew</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Lim</surname>
              <given-names>C.K.</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>E.A.</given-names>
            </name>
            <name>
              <surname>Styles</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>White</surname>
              <given-names>I.N.</given-names>
            </name>
          </person-group>
          <article-title>Chemoprevention of breast cancer by tamoxifen: risks and opportunities</article-title>
          <source>Crit. Rev. Toxicol.</source>
          <volume>30</volume>
          <year>2000</year>
          <fpage>571</fpage>
          <lpage>594</lpage>
          <pub-id pub-id-type="pmid">11055836</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0755">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Soballe</surname>
              <given-names>P.W.</given-names>
            </name>
            <name>
              <surname>Maloy</surname>
              <given-names>W.L.</given-names>
            </name>
            <name>
              <surname>Myrga</surname>
              <given-names>M.L.</given-names>
            </name>
            <name>
              <surname>Jacob</surname>
              <given-names>L.S.</given-names>
            </name>
            <name>
              <surname>Herlyn</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Experimental local therapy of human melanoma with lytic magainin peptides</article-title>
          <source>Int. J. Cancer</source>
          <volume>60</volume>
          <year>1995</year>
          <fpage>280</fpage>
          <lpage>284</lpage>
          <pub-id pub-id-type="pmid">7829229</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0760">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Soengas</surname>
              <given-names>M.S.</given-names>
            </name>
            <name>
              <surname>Capodieci</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Polsky</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Mora</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Esteller</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Opitz-Araya</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>McCombie</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Herman</surname>
              <given-names>J.G.</given-names>
            </name>
            <name>
              <surname>Gerald</surname>
              <given-names>W.L.</given-names>
            </name>
            <name>
              <surname>Lazebnik</surname>
              <given-names>Y.A.</given-names>
            </name>
            <name>
              <surname>Cordon-Cardo</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Lowe</surname>
              <given-names>S.W.</given-names>
            </name>
          </person-group>
          <article-title>Inactivation of the apoptosis effector Apaf-1 in malignant melanoma</article-title>
          <source>Nature</source>
          <volume>409</volume>
          <year>2001</year>
          <fpage>207</fpage>
          <lpage>211</lpage>
          <pub-id pub-id-type="pmid">11196646</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0765">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sok</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Sentjurc</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Schara</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Stare</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Rott</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Cell membrane fluidity and prognosis of lung cancer</article-title>
          <source>Ann. Thorac. Surg.</source>
          <volume>73</volume>
          <year>2002</year>
          <fpage>1567</fpage>
          <lpage>1571</lpage>
          <pub-id pub-id-type="pmid">12022551</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0770">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Staudegger</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Prenner</surname>
              <given-names>E.J.</given-names>
            </name>
            <name>
              <surname>Kriechbaum</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Degovics</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Lewis</surname>
              <given-names>R.N.A.H.</given-names>
            </name>
            <name>
              <surname>McElhaney</surname>
              <given-names>R.N.</given-names>
            </name>
            <name>
              <surname>Lohner</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>X-ray studies on the interaction of the antimicrobial peptide gramicidin S with microbial lipid extracts: evidence for cubic phase formation</article-title>
          <source>Biochim. Biophys. Acta</source>
          <volume>1468</volume>
          <year>2000</year>
          <fpage>213</fpage>
          <lpage>230</lpage>
          <pub-id pub-id-type="pmid">11018666</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0775">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sugahara</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Mikami</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Uyama</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Mizuguchi</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Nomura</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Kitagawa</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Recent advances in the structural biology of chondroitin sulfate and dermatan sulfate</article-title>
          <source>Curr. Opin. Struct. Biol.</source>
          <volume>13</volume>
          <year>2003</year>
          <fpage>612</fpage>
          <lpage>620</lpage>
          <pub-id pub-id-type="pmid">14568617</pub-id>
        </element-citation>
      </ref>
      <ref id="bib1040">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Suttmann</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Retz</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Paulsen</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Harder</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Zwergel</surname>
              <given-names>U.</given-names>
            </name>
            <name>
              <surname>Kamradt</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Wullich</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Unteregger</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Stockle</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Lehmann</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Antimicrobial peptides of the Cecropin-family show potent antitumor activity against bladder cancer cells</article-title>
          <source>BMC Urol.</source>
          <volume>8</volume>
          <year>2008</year>
          <fpage>5</fpage>
          <pub-id pub-id-type="pmid">18315881</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0780">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Szachowicz-Petelska</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Dobrzynska</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Figaszewski</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Sulkowski</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Changes in physico-chemical properties of human large intestine tumour cells membrane</article-title>
          <source>Mol. Cell. Biochem.</source>
          <volume>238</volume>
          <year>2002</year>
          <fpage>41</fpage>
          <lpage>47</lpage>
          <pub-id pub-id-type="pmid">12349908</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0785">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Szakacs</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Paterson</surname>
              <given-names>J.K.</given-names>
            </name>
            <name>
              <surname>Ludwig</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Booth-Genthe</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Gottesman</surname>
              <given-names>M.M.</given-names>
            </name>
          </person-group>
          <article-title>Targeting multidrug resistance in cancer</article-title>
          <source>Nat. Rev. Drug Discov.</source>
          <volume>5</volume>
          <year>2006</year>
          <fpage>219</fpage>
          <lpage>234</lpage>
          <pub-id pub-id-type="pmid">16518375</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0790">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tanaka</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Fujimoto</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Suzuki</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Suzuki</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Ohtake</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Saito</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Kohgo</surname>
              <given-names>Y.</given-names>
            </name>
          </person-group>
          <article-title>PI3-kinase p85α is a target molecule of proline-rich antimicrobial peptide to suppress proliferation of ras-transformed cells</article-title>
          <source>Jpn. J. Cancer Res.</source>
          <volume>92</volume>
          <year>2001</year>
          <fpage>959</fpage>
          <lpage>967</lpage>
          <pub-id pub-id-type="pmid">11572764</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0795">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thévenin</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>An</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Engelman</surname>
              <given-names>D.M.</given-names>
            </name>
          </person-group>
          <article-title>pHLIP-mediated translocation of membrane-impermeable molecules into cells</article-title>
          <source>Chem. Biol.</source>
          <volume>16</volume>
          <year>2009</year>
          <fpage>754</fpage>
          <lpage>762</lpage>
          <pub-id pub-id-type="pmid">19635412</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0800">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tkachenko</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Rhodes</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Simons</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Syndecans: new kids on the signaling block</article-title>
          <source>Circ. Res.</source>
          <volume>96</volume>
          <year>2005</year>
          <fpage>488</fpage>
          <lpage>500</lpage>
          <pub-id pub-id-type="pmid">15774861</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0805">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tofilon</surname>
              <given-names>P.J.</given-names>
            </name>
            <name>
              <surname>Camphausen</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Molecular targets for tumor radiosensitization</article-title>
          <source>Chem. Rev.</source>
          <volume>109</volume>
          <year>2009</year>
          <fpage>2974</fpage>
          <lpage>2988</lpage>
          <pub-id pub-id-type="pmid">19338375</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0810">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tosteson</surname>
              <given-names>M.T.</given-names>
            </name>
            <name>
              <surname>Tosteson</surname>
              <given-names>D.C.</given-names>
            </name>
          </person-group>
          <article-title>The sting. Melittin forms channels in lipid bilayers</article-title>
          <source>Biophys. J.</source>
          <volume>36</volume>
          <year>1981</year>
          <fpage>109</fpage>
          <lpage>116</lpage>
          <pub-id pub-id-type="pmid">6269667</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0815">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Utsugi</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Schroit</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Connor</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Bucana</surname>
              <given-names>C.D.</given-names>
            </name>
            <name>
              <surname>Fidler</surname>
              <given-names>I.J.</given-names>
            </name>
          </person-group>
          <article-title>Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes</article-title>
          <source>Cancer Res.</source>
          <volume>51</volume>
          <year>1991</year>
          <fpage>3062</fpage>
          <lpage>3066</lpage>
          <pub-id pub-id-type="pmid">2032247</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0820">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>van Blitterswijk</surname>
              <given-names>W.J.</given-names>
            </name>
          </person-group>
          <chapter-title>Alteration in lipid fluidity in the plasma membrane of tumor cells</chapter-title>
          <person-group person-group-type="editor">
            <name>
              <surname>Shinitzky</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <source>Physiology of Membrane Fluidity</source>
          <year>1984</year>
          <publisher-name>CRC Press</publisher-name>
          <publisher-loc>Boca Raton, FL, USA</publisher-loc>
          <fpage>53</fpage>
          <lpage>84</lpage>
        </element-citation>
      </ref>
      <ref id="bib0825">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Van de</surname>
              <given-names>W.C.</given-names>
            </name>
            <name>
              <surname>Lahorte</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Vermeersch</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Loose</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Mervillie</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Steinmetz</surname>
              <given-names>N.D.</given-names>
            </name>
            <name>
              <surname>Vanderheyden</surname>
              <given-names>J.L.</given-names>
            </name>
            <name>
              <surname>Cuvelier</surname>
              <given-names>C.A.</given-names>
            </name>
            <name>
              <surname>Slegers</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Dierck</surname>
              <given-names>R.A.</given-names>
            </name>
          </person-group>
          <article-title>Quantitative tumor apoptosis imaging using technetium-99m-HYNIC annexin V single photon emission computed tomography</article-title>
          <source>J. Clin. Oncol.</source>
          <volume>21</volume>
          <year>2003</year>
          <fpage>3483</fpage>
          <lpage>3487</lpage>
          <pub-id pub-id-type="pmid">12972524</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0830">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vogel</surname>
              <given-names>H.J.</given-names>
            </name>
            <name>
              <surname>Schibli</surname>
              <given-names>D.J.</given-names>
            </name>
            <name>
              <surname>Jing</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Lohmeier-Vogel</surname>
              <given-names>E.M.</given-names>
            </name>
            <name>
              <surname>Epand</surname>
              <given-names>R.F.</given-names>
            </name>
            <name>
              <surname>Epand</surname>
              <given-names>R.M.</given-names>
            </name>
          </person-group>
          <article-title>Towards a structure-function analysis of bovine lactoferricin and related tryptophan- and arginine-containing peptides</article-title>
          <source>Biochem. Cell. Biol.</source>
          <volume>80</volume>
          <year>2002</year>
          <fpage>49</fpage>
          <lpage>63</lpage>
          <pub-id pub-id-type="pmid">11908643</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0835">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>F.L.</given-names>
            </name>
            <name>
              <surname>Cui</surname>
              <given-names>S.X.</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>L.P.</given-names>
            </name>
            <name>
              <surname>Qu</surname>
              <given-names>X.J.</given-names>
            </name>
            <name>
              <surname>Xie</surname>
              <given-names>Y.Y.</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Mu</surname>
              <given-names>Y.L.</given-names>
            </name>
            <name>
              <surname>Tang</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Y.S.</given-names>
            </name>
          </person-group>
          <article-title>High expression of alpha 2,3-linked sialic acid residues is associated with the metastatic potential of human gastric cancer</article-title>
          <source>Cancer Detect. Prev.</source>
          <volume>32</volume>
          <year>2009</year>
          <fpage>437</fpage>
          <lpage>443</lpage>
          <pub-id pub-id-type="pmid">19232843</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0840">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Z.</given-names>
            </name>
          </person-group>
          <article-title>APD2: the updated antimicrobial peptide database and its application in peptide design</article-title>
          <source>Nucleic Acids Res.</source>
          <volume>37</volume>
          <year>2009</year>
          <fpage>D933</fpage>
          <lpage>D937</lpage>
          <pub-id pub-id-type="pmid">18957441</pub-id>
        </element-citation>
      </ref>
      <ref id="bib1045">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>K.R.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>B.Z.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Yan</surname>
              <given-names>J.X.</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Antitumor effects, cell selectivity and structure-activity relationship of a novel antimicrobial peptide polybia-MPI</article-title>
          <source>Peptides</source>
          <volume>29</volume>
          <year>2008</year>
          <fpage>963</fpage>
          <lpage>968</lpage>
          <pub-id pub-id-type="pmid">18328599</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0845">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>K.R.</given-names>
            </name>
            <name>
              <surname>Yan</surname>
              <given-names>J.X.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>B.Z.</given-names>
            </name>
            <name>
              <surname>Song</surname>
              <given-names>J.J.</given-names>
            </name>
            <name>
              <surname>Jia</surname>
              <given-names>P.f.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Novel mode of action of polybia-MPI, a novel antimicrobial peptide, in multi-drug resistant leukemic cells</article-title>
          <source>Cancer Lett.</source>
          <volume>278</volume>
          <year>2009</year>
          <fpage>65</fpage>
          <lpage>72</lpage>
          <pub-id pub-id-type="pmid">19233550</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0850">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>APD: the antimicrobial peptide database</article-title>
          <source>Nucleic Acids Res.</source>
          <volume>32</volume>
          <year>2004</year>
          <fpage>D590</fpage>
          <lpage>D592</lpage>
          <pub-id pub-id-type="pmid">14681488</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0855">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wieczorek</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Jenssen</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Kindrachuk</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Scott</surname>
              <given-names>W.R.P.</given-names>
            </name>
            <name>
              <surname>Elliott</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Hilpert</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Cheng</surname>
              <given-names>J.T.J.</given-names>
            </name>
            <name>
              <surname>Hancock</surname>
              <given-names>R.E.W.</given-names>
            </name>
            <name>
              <surname>Straus</surname>
              <given-names>S.K.</given-names>
            </name>
          </person-group>
          <article-title>Structural studies of a peptide with immune modulating and direct antimicrobial activity</article-title>
          <source>Chem. Biol.</source>
          <volume>17</volume>
          <year>2010</year>
          <fpage>970</fpage>
          <lpage>980</lpage>
          <pub-id pub-id-type="pmid">20851346</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0860">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Willumeit</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Kumpugdee</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Funari</surname>
              <given-names>S.S.</given-names>
            </name>
            <name>
              <surname>Lohner</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Pozo-Navas</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Brandenburg</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Linser</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Andrä</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Structural rearrangement of model membranes by the peptide antibiotic NK-2</article-title>
          <source>Biochim. Biophys. Acta</source>
          <volume>1669</volume>
          <year>2005</year>
          <fpage>125</fpage>
          <lpage>134</lpage>
          <pub-id pub-id-type="pmid">15893515</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0865">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wimley</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Hristova</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Antimicrobial peptides: successes, challenges and unanswered questions</article-title>
          <source>J. Membr. Biol.</source>
          <volume>239</volume>
          <year>2011</year>
          <fpage>27</fpage>
          <lpage>34</lpage>
          <pub-id pub-id-type="pmid">21225255</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0870">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wimley</surname>
              <given-names>W.C.</given-names>
            </name>
          </person-group>
          <article-title>Describing the mechanism of antimicrobial peptide action with the interfacial activity model</article-title>
          <source>ACS Chem. Biol.</source>
          <volume>5</volume>
          <year>2010</year>
          <fpage>905</fpage>
          <lpage>917</lpage>
          <pub-id pub-id-type="pmid">20698568</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0875">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wimley</surname>
              <given-names>W.C.</given-names>
            </name>
            <name>
              <surname>Creamer</surname>
              <given-names>T.P.</given-names>
            </name>
            <name>
              <surname>White</surname>
              <given-names>S.H.</given-names>
            </name>
          </person-group>
          <article-title>Solvation energies of amino acid side chains and backbone in a family of host-guest pentapeptides</article-title>
          <source>Biochemistry</source>
          <volume>35</volume>
          <year>1996</year>
          <fpage>5109</fpage>
          <lpage>5124</lpage>
          <pub-id pub-id-type="pmid">8611495</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0880">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Winder</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Günzburg</surname>
              <given-names>W.H.</given-names>
            </name>
            <name>
              <surname>Erfle</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Salmons</surname>
              <given-names>B.</given-names>
            </name>
          </person-group>
          <article-title>Expression of antimicrobial peptides has an antitumour effect in human cells</article-title>
          <source>Biochem. Biophys. Res. Commun.</source>
          <volume>242</volume>
          <year>1998</year>
          <fpage>608</fpage>
          <lpage>612</lpage>
          <pub-id pub-id-type="pmid">9464264</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0885">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Woehlecke</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Pohl</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Alder-Baerens</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Lage</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Herrmann</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Enhanced exposure of phosphatidylserine in human gastric carcinoma cells overexpressing the half-size ABC transporter BCRP (ABCG2)</article-title>
          <source>Biochem. J.</source>
          <volume>376</volume>
          <year>2003</year>
          <fpage>489</fpage>
          <lpage>495</lpage>
          <pub-id pub-id-type="pmid">12946267</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0890">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xu</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Y.S.</given-names>
            </name>
            <name>
              <surname>Pan</surname>
              <given-names>W.B.</given-names>
            </name>
            <name>
              <surname>Xiao</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Wen</surname>
              <given-names>Y.J.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>X.C.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>L.J.</given-names>
            </name>
            <name>
              <surname>Deng</surname>
              <given-names>H.X.</given-names>
            </name>
            <name>
              <surname>You</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Kan</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Fu</surname>
              <given-names>A.F.</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Wei</surname>
              <given-names>Y.Q.</given-names>
            </name>
          </person-group>
          <article-title>Human alpha-defensin-1 inhibits growth of human lung adenocarcinoma xenograft in nude mice</article-title>
          <source>Mol. Cancer Ther.</source>
          <volume>7</volume>
          <year>2008</year>
          <fpage>1588</fpage>
          <lpage>1597</lpage>
          <pub-id pub-id-type="pmid">18566229</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0895">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yang</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Lejon</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Rekdal</surname>
              <given-names>O.</given-names>
            </name>
          </person-group>
          <article-title>Antitumour activity and specificity as a function of substitutions in the lipophilic sector of helical lactoferrin-derived peptide</article-title>
          <source>J. Pept. Sci.</source>
          <volume>9</volume>
          <year>2003</year>
          <fpage>300</fpage>
          <lpage>311</lpage>
          <pub-id pub-id-type="pmid">12803496</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0900">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yang</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Strom</surname>
              <given-names>M.B.</given-names>
            </name>
            <name>
              <surname>Mekonnen</surname>
              <given-names>S.M.</given-names>
            </name>
            <name>
              <surname>Svendsen</surname>
              <given-names>J.S.</given-names>
            </name>
            <name>
              <surname>Rekdal</surname>
              <given-names>O.</given-names>
            </name>
          </person-group>
          <article-title>The effects of shortening lactoferrin derived peptides against tumour cells, bacteria and normal human cells</article-title>
          <source>J. Pept. Sci.</source>
          <volume>10</volume>
          <year>2004</year>
          <fpage>37</fpage>
          <lpage>46</lpage>
          <pub-id pub-id-type="pmid">14959890</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0905">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yoo</surname>
              <given-names>Y.-C.</given-names>
            </name>
            <name>
              <surname>Watanabe</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Watanabe</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Hata</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Shimazaki</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Azuma</surname>
              <given-names>I.</given-names>
            </name>
          </person-group>
          <article-title>Bovine lactoferrin and lactoferricin, a peptide derived from bovine lactoferrin, inhibit tumor metastasis in mice</article-title>
          <source>Jpn. J. Cancer Res.</source>
          <volume>88</volume>
          <year>1997</year>
          <fpage>184</fpage>
          <lpage>190</lpage>
          <pub-id pub-id-type="pmid">9119747</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0910">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zasloff</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor</article-title>
          <source>Proc. Natl. Acad. Sci. U.S.A.</source>
          <volume>84</volume>
          <year>1987</year>
          <fpage>5449</fpage>
          <lpage>5453</lpage>
          <pub-id pub-id-type="pmid">3299384</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0915">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zasloff</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Antimicrobial peptides of multicellular organisms</article-title>
          <source>Nature</source>
          <volume>415</volume>
          <year>2002</year>
          <fpage>389</fpage>
          <lpage>395</lpage>
          <pub-id pub-id-type="pmid">11807545</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0920">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>L.W.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>K.R.</given-names>
            </name>
            <name>
              <surname>Song</surname>
              <given-names>J.J.</given-names>
            </name>
            <name>
              <surname>Yan</surname>
              <given-names>J.X.</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>Z.Y.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>B.Z.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>A novel analog of antimicrobial peptide Polybia-MPI, with thioamide bond substitution, exhibits increased therapeutic efficacy against cancer and diminished toxicity in mice</article-title>
          <source>Peptides</source>
          <volume>31</volume>
          <year>2010</year>
          <fpage>1832</fpage>
          <lpage>1838</lpage>
          <pub-id pub-id-type="pmid">20600424</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0925">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zoonens</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Reshetnyak</surname>
              <given-names>Y.K.</given-names>
            </name>
            <name>
              <surname>Engelman</surname>
              <given-names>D.M.</given-names>
            </name>
          </person-group>
          <article-title>Bilayer interactions of pHLIP, a peptide that can deliver drugs and target tumors</article-title>
          <source>Biophys. J.</source>
          <volume>95</volume>
          <year>2008</year>
          <fpage>225</fpage>
          <lpage>235</lpage>
          <pub-id pub-id-type="pmid">18359793</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0930">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zwaal</surname>
              <given-names>R.F.</given-names>
            </name>
            <name>
              <surname>Schroit</surname>
              <given-names>A.J.</given-names>
            </name>
          </person-group>
          <article-title>Pathophysiologic implications of membrane phospholipid asymmetry in blood cells</article-title>
          <source>Blood</source>
          <volume>89</volume>
          <year>1997</year>
          <fpage>1121</fpage>
          <lpage>1132</lpage>
          <pub-id pub-id-type="pmid">9028933</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0935">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zweytick</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Pabst</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Abuja</surname>
              <given-names>P.M.</given-names>
            </name>
            <name>
              <surname>Jilek</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Blondelle</surname>
              <given-names>S.E.</given-names>
            </name>
            <name>
              <surname>Andrä</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Jerala</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Monreal</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Martinez de Tejada</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Lohner</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Influence of N-acylation of a peptide derived from human lactoferricin on membrane selectivity</article-title>
          <source>Biochim. Biophys. Acta</source>
          <volume>1758</volume>
          <year>2006</year>
          <fpage>1426</fpage>
          <lpage>1435</lpage>
          <pub-id pub-id-type="pmid">16616888</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0940">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zweytick</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Riedl</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Rinner</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Asslaber</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Schaider</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Walzer</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Novak</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Lohner</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>In search of new targets – the membrane lipid phosphatidylserine – the underestimated Achilles’ heel of cancer cells</article-title>
          <source>Ann. Oncol.</source>
          <volume>22</volume>
          <issue>suppl. 3</issue>
          <year>2011</year>
          <fpage>iii42</fpage>
          <lpage>iii43</lpage>
        </element-citation>
      </ref>
      <ref id="bib0945">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zweytick</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Tumer</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Blondelle</surname>
              <given-names>S.E.</given-names>
            </name>
            <name>
              <surname>Lohner</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Membrane curvature stress and antibacterial activity of lactoferricin derivatives</article-title>
          <source>Biochem. Biophys. Res. Commun.</source>
          <volume>369</volume>
          <year>2008</year>
          <fpage>395</fpage>
          <lpage>400</lpage>
          <pub-id pub-id-type="pmid">18282464</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0950">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zweytick</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Deutsch</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Andrä</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Blondelle</surname>
              <given-names>S.E.</given-names>
            </name>
            <name>
              <surname>Vollmer</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Jerala</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Lohner</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Studies on lactoferricin derived <italic>E. coli</italic> membrane active peptides reveal differences in the mechanism of N-acylated versus non-acylated peptides</article-title>
          <source>J. Biol. Chem.</source>
          <volume>24</volume>
          <year>2011</year>
          <fpage>21266</fpage>
          <lpage>21276</lpage>
          <pub-id pub-id-type="pmid">21515687</pub-id>
        </element-citation>
      </ref>
    </ref-list>
    <ack>
      <title>Acknowledgments</title>
      <p>The authors gratefully acknowledge financial support from the Austrian Science Fund (FWF grant no. P20760-B11) and from the Sonnleitner as well as the Oelzelt Stiftung of the Austrian Academy of Sciences.</p>
    </ack>
  </back>
  <floats-group>
    <fig id="fig0005">
      <label>Fig. 1</label>
      <caption>
        <p>New anticancer drugs (1940s-06/2006) subdivided by source adapted from (<xref rid="bib0525" ref-type="bibr">Newman and Cragg, 2007</xref>): (B) biological; (N) natural product; (ND) derived from natural product – semisynthetic modifications; (S) synthetic drug; (S/NM) synthetic/natural drug mimic; (S*) made by total synthesis; (S*/NM) made by total synthesis/natural drug mimic; (V) vaccine.</p>
      </caption>
      <graphic xlink:href="gr1"/>
    </fig>
    <fig id="fig0010">
      <label>Fig. 2</label>
      <caption>
        <p>Sketch of specific characteristics of cancer cells concerning membrane and genetic changes. Selectivity of cationic anticancer peptides can be driven by direct interaction with anionic target molecules exposed on the cell surface such as PS. Exposure of PS (1) is related to several cell processes, which involves activation of a putative scramblase and inactivation of a putative ATP-dependent phospholipid (PL) – translocase. Increased levels of sialic acid of glycolipids and proteins on cancer surfaces (2), normally providing a protective shield, can also be a target for the positively charged peptides. Furthermore, changes in membrane fluidity (3) and pH (4) influence susceptibility and activity of peptides, which may also be affected by the increased surface area of cancer cells owing to the higher number of microvilli (5) present. Finally, peptides, which translocate into the cytosolic compartment, may interact with anionic lipids of mitochondria, triggering apoptosis, a process normally blocked by several changes in tumor cells such as e.g. inactivation of the tumor suppressor p53 (6). For details see main text.</p>
      </caption>
      <graphic xlink:href="gr2"/>
    </fig>
    <fig id="fig0015">
      <label>Fig. 3</label>
      <caption>
        <p>PS exposure of melanoma cell lines: correlation of PS exposure with tumor progression of melanoma cell lines expressed as multiples of PS exposure of normal melanocytes as determined by Annexin A5 binding (SBcl-2, WM35 from primary and WM9, WM164 from metastatic lesions; error bars resulting from four independent experiments).</p>
      </caption>
      <graphic xlink:href="gr3"/>
      <attrib>Data adopted from <xref rid="bib0640" ref-type="bibr">Riedl et al. (2011a)</xref> and <xref rid="bib0940" ref-type="bibr">Zweytick et al. (2011a)</xref>.</attrib>
    </fig>
    <fig id="fig0020">
      <label>Fig. 4</label>
      <caption>
        <p>Mode of action of membrane-active host defense peptides: boundaries of the schematic phase diagram of amphipathic peptide/phospholipid aggregates are given as a function of the concentration of membrane-associated peptide and the composition of the membrane from mixtures of cylindrical (phosphatidylserine, phosphatidylcholine) and truncated inverted cone lipids (cardiolipin, phosphatidylethanolamine); modified from <xref rid="bib0045" ref-type="bibr">Bechinger (2009)</xref>. Membrane association of the cationic peptides is strongly increased in the presence of anionic phospholipids such as PS or cardiolipin. In the presence of cholesterol, an abundant membrane component in mammalian cells, the bilayer will be stabilized, i.e. the phase region of stable bilayers will be enhanced. Some molecular mechanisms of bilayer perturbation are schematically shown (for details see Section <xref rid="sec0060" ref-type="sec">4.1</xref>).</p>
      </caption>
      <graphic xlink:href="gr4"/>
    </fig>
    <fig id="fig0025">
      <label>Fig. 5</label>
      <caption>
        <p>Characteristics of anticancer peptides: (A) peptide length; (B) net charge; (C) hydrophobic content (% hydrophobic amino acids; <ext-link ext-link-type="uri" xlink:href="http://aps.unmc.edu/AP/design/design_improve.php">http://aps.unmc.edu/AP/design/design_improve.php</ext-link>); (D) hydrophobicity of peptides expressed as transfer free energy of peptides from water to <italic>n</italic>-octanol (Δ<italic>G</italic><sub>woct</sub>) taking into account the contribution of both endgroups (COO<sup>−</sup> and NH<sub>3</sub><sup>+</sup>), in case of C-amidation or N-acetylation Δ<italic>G</italic><sub>woct</sub> decreases by 3.6 kcal/mol and 2.3 kcal/mol, respectively (<ext-link ext-link-type="uri" xlink:href="http://blanco.biomol.uci.edu/mpex/">http://blanco.biomol.uci.edu/mpex/</ext-link>) (<xref rid="bib0875" ref-type="bibr">Wimley et al., 1996</xref>), n.c., not calculated for peptides &gt;70 amino acids; (E) structural characteristics.</p>
      </caption>
      <graphic xlink:href="gr5"/>
    </fig>
    <fig id="fig0030">
      <label>Fig. 6</label>
      <caption>
        <p>Pair correlations between peptide length and net charge (A) and hydrophobicity (B), respectively, for antitumor peptides listed in the Antimicrobial Peptide Database, APD2 (<xref rid="bib0840" ref-type="bibr">Wang et al., 2009b</xref>) excluding the three peptides &gt;70 amino acids for which no Δ<italic>G</italic><sub>woct</sub> can be calculated. The secondary structure of the individual peptides is indicated in the panels by the following symbols: ♦, α-helix; ■, β-sheet; ▴, α-helix and β-sheet; ●, unknown; ×, others.</p>
      </caption>
      <graphic xlink:href="gr6"/>
    </fig>
    <table-wrap id="tbl0005" position="float" orientation="landscape">
      <?landscape?>
      <?legal?>
      <label>Table 1</label>
      <caption>
        <p>Selected host defense peptides tested in <italic>in vitro</italic> studies for anticancer activity.<xref rid="tblfn0005" ref-type="table-fn">a</xref></p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="left">Peptide/<italic>Source</italic></th>
            <th align="left">Sequence</th>
            <th align="left"><italic>In vitro</italic> study</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td colspan="3" align="left">α-Helical</td>
          </tr>
          <tr>
            <td align="left">Aureins<italic>Southern bell frog</italic></td>
            <td align="left">GLFDIIKKIAESF(aurein 1.2)</td>
            <td align="left">60 cancer cell lines tested (human tumor line testing program of the US National Cancer Institute) (∼50 active) (<xref rid="bib1030" ref-type="bibr">Rozek et al., 2000</xref>)</td>
          </tr>
          <tr>
            <td align="left">BMAP-27/BMAP-28<italic>Bovine</italic></td>
            <td align="left">GRFKRFRKKFKKLFKKLSPVIPLLHLG/GGLRSLGRKILRAWKKYGPIIVPIIRIG</td>
            <td align="left">Human tumor cells, leukemic cells (<xref rid="bib0650" ref-type="bibr">Risso et al., 1998</xref>)</td>
          </tr>
          <tr>
            <td align="left">Cecropin A<italic>Hyalophora cecropia</italic>Cecropin B<italic>Chinese oak silk moth</italic></td>
            <td align="left">KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAKKWKIFKKIEKVGRNIRNGIIKAGPAVAVLGEAKAL</td>
            <td align="left">Bladder cancer (<xref rid="bib1040" ref-type="bibr">Suttmann et al., 2008</xref>)Leukemia (<xref rid="bib0955" ref-type="bibr">Chen et al., 1997</xref>), bladder cancer (<xref rid="bib1040" ref-type="bibr">Suttmann et al., 2008</xref>)</td>
          </tr>
          <tr>
            <td align="left">Citropins<italic>Australian blue mountains tree frog</italic></td>
            <td align="left">GLFDVIKKVASVIGGL(Citropin 1.1)</td>
            <td align="left">60 human cancer cell lines (human tumor line testing program of the US National Cancer Institute) (<xref rid="bib0965" ref-type="bibr">Doyle et al., 2003</xref>); human histiocytic lymphoma cell line (<xref rid="bib0985" ref-type="bibr">Koszalka et al., 2011</xref>)</td>
          </tr>
          <tr>
            <td align="left">Epinicidin-1<italic>Fish</italic></td>
            <td align="left">GFIFHIIKGLFHAGKMIHGLV</td>
            <td align="left">Human lung carcinoma, cervix adenocarcinoma, hepatocellular carcinoma, fibrosarcoma, histiocytic lymphoma cells (<xref rid="bib1010" ref-type="bibr">Lin et al., 2009</xref>)</td>
          </tr>
          <tr>
            <td align="left">Gaegurin-6/-5<italic>Korean wrinkled frog</italic></td>
            <td align="left">FLPLLAGLAANFLPTIICKISYKC</td>
            <td align="left">Human lung, prostate, liver, kidney and breast cancer cell lines (<xref rid="bib0980" ref-type="bibr">Kim et al., 2003</xref>)</td>
          </tr>
          <tr>
            <td align="left">LL-37<italic>Homo sapiens</italic></td>
            <td align="left">LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES</td>
            <td align="left">Jurkat human T leukemia cells, HeLa cells (<xref rid="bib1015" ref-type="bibr">Mader et al., 2009</xref>)</td>
          </tr>
          <tr>
            <td align="left">Magainins<italic>African clawed frog</italic>Pexiganan (MSI-78)</td>
            <td align="left">GIGKFLHSAKKFGKAFVGEIMNS(Magainin 2)GIGKFLKKAKKFGKAFVKILKK</td>
            <td align="left">Hematopoietic cell lines (<xref rid="bib0150" ref-type="bibr">Cruciani et al., 1991</xref>), Ehrlich ascites tumor cells, human adenocarcinoma (<xref rid="bib0035" ref-type="bibr">Baker et al., 1993</xref>), bladder cancer line (<xref rid="bib0990" ref-type="bibr">Lehmann et al., 2006</xref>), histiocytic lymphoma cell line (<xref rid="bib0985" ref-type="bibr">Koszalka et al., 2011</xref>)</td>
          </tr>
          <tr>
            <td align="left">Melittin<italic>Honey bee venom</italic></td>
            <td align="left">GIGAVLKVLTTGLPALISWIKRKRQQ</td>
            <td align="left">Human hepatocellular carcinoma (<xref rid="bib0835" ref-type="bibr">Wang et al., 2009a</xref>); osteosarcoma (<xref rid="bib0960" ref-type="bibr">Chu et al., 2007</xref>); leukemic cells (<xref rid="bib1025" ref-type="bibr">Moon et al., 2008</xref>); prostate and ovarian (<xref rid="bib0290" ref-type="bibr">Holle et al., 2003</xref>), neuroblastoma cancer cells (<xref rid="bib0970" ref-type="bibr">Drechsler and Andrä, 2011</xref>)</td>
          </tr>
          <tr>
            <td align="left">NK-2<italic>Porcine leukocytes</italic>NKCS and derivatives</td>
            <td align="left">KILRGVCKKIMRTFLRRISKDILTGKKKILRGVSKKIMRTFLRRISKDILTGKK</td>
            <td align="left">Human lymphocytes and seven human cancer cell lines (<xref rid="bib0680" ref-type="bibr">Schröder-Borm et al., 2005</xref>); human neuroblastoma cancer cells (<xref rid="bib0970" ref-type="bibr">Drechsler and Andrä, 2011</xref>)Human prostate carcinoma cells (<xref rid="bib1020" ref-type="bibr">Manavbasi et al., 2010</xref>)</td>
          </tr>
          <tr>
            <td align="left">Pep27<italic>Strep. pneumonia</italic></td>
            <td align="left">MRKEFHNVLSSGQLLADKRPARDYNRK</td>
            <td align="left">Leukemia cell lines (<xref rid="bib0995" ref-type="bibr">Lee et al., 2005</xref>)</td>
          </tr>
          <tr>
            <td align="left">Polybia-MPI<italic>P. paulista</italic></td>
            <td align="left">IDWKKLLDAAKQIL</td>
            <td align="left">Human bladder cancer and prostate cancer cell line (<xref rid="bib1045" ref-type="bibr">Wang et al., 2008</xref>)</td>
          </tr>
          <tr>
            <td align="left">Temporin A<italic>Frog Rana temporaria</italic></td>
            <td align="left">FLPLIGRVLSGIL</td>
            <td align="left">Human histiocytic lymphoma cell line (<xref rid="bib0985" ref-type="bibr">Koszalka et al., 2011</xref>)</td>
          </tr>
          <tr>
            <td colspan="3" align="left">β-sheet</td>
          </tr>
          <tr>
            <td align="left">Buforin II<italic>Bufo bufo gargarizans</italic></td>
            <td align="left">TRSSRAGLQFPVGRVHRLLRK</td>
            <td align="left">62 cell lines (<xref rid="bib1000" ref-type="bibr">Lee et al., 2008</xref>); human histiocytic lymphoma cell line (<xref rid="bib0985" ref-type="bibr">Koszalka et al., 2011</xref>)</td>
          </tr>
          <tr>
            <td align="left">Human α-defensins<italic>Homo sapiens</italic>Defensins</td>
            <td align="left">ACYCRIPACIAGERRYGTCIYQGRLWAFCC(HNP1)Diverse sequences</td>
            <td align="left">Human lung adenocarcinoma (<xref rid="bib0890" ref-type="bibr">Xu et al., 2008</xref>)HeLa, glioma, kidney cancer, lung cancer, myeloma (<xref rid="bib0320" ref-type="bibr">Iwasaki et al., 2009</xref>)</td>
          </tr>
          <tr>
            <td align="left">Gomesin<italic>A. gomesiana</italic></td>
            <td align="left">ECRRLCYKQRCVTYCRGR</td>
            <td align="left">Breast and colon adenocarcinoma, HeLa (<xref rid="bib0655" ref-type="bibr">Rodrigues et al., 2002</xref>)</td>
          </tr>
          <tr>
            <td align="left">Lactoferricin B<italic>Bovine</italic></td>
            <td align="left">FKCRRWQWRMKKLGAPSITCVRRAF</td>
            <td align="left">Neuroblastoma (<xref rid="bib0195" ref-type="bibr">Eliassen et al., 2006</xref>), melanoma, mammary carcinoma, colorectal adenocarcinoma (<xref rid="bib0975" ref-type="bibr">Eliassen et al., 2003</xref>)</td>
          </tr>
          <tr>
            <td align="left">Protegrin-1<italic>porcine</italic></td>
            <td align="left">RGGRLCYCRRRFCVCVGR</td>
            <td align="left">Human histiocytic lymphoma cell line (<xref rid="bib0985" ref-type="bibr">Koszalka et al., 2011</xref>)</td>
          </tr>
          <tr>
            <td align="left">Tachyplesin I<italic>Southeast Asian horseshoe crab</italic></td>
            <td align="left">KWCFRVCYRGICYRRCR</td>
            <td align="left">Human gastric adenocarcinoma (<xref rid="bib1035" ref-type="bibr">Shi et al., 2006</xref>); human hepatocarcinoma cells (<xref rid="bib1005" ref-type="bibr">Li et al., 2003</xref>);</td>
          </tr>
          <tr>
            <td colspan="3" align="left">Others</td>
          </tr>
          <tr>
            <td align="left">PR-39<italic>Porcine small intestine</italic></td>
            <td align="left">
              <italic>RRRPRPPYLPRPRPPPFFPPRLPPRIPPGFPPRFPPRFP</italic>
            </td>
            <td align="left">Human hepatocellular carcinoma cells (<xref rid="bib0535" ref-type="bibr">Ohtake et al., 1999</xref>)</td>
          </tr>
          <tr>
            <td align="left">Alloferon-1/-2<italic>Insects</italic></td>
            <td align="left">
              <italic>HGVSGHGOHGVHG/GVSGHGVHG</italic>
            </td>
            <td align="left">Mice (IFN-production) (<xref rid="bib0135" ref-type="bibr">Chernysh et al., 2002</xref>)</td>
          </tr>
          <tr>
            <td align="left">Dolastatin 10<italic>D. auricularia</italic></td>
            <td align="left">Dov-Val-Dil-Dap-Doe<xref rid="tblfn0010" ref-type="table-fn">b</xref></td>
            <td align="left">Murine PS leukemia cells (<xref rid="bib0590" ref-type="bibr">Pettit et al., 1987</xref>)</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn id="tblfn0005">
          <label>a</label>
          <p>For a complete list of anticancer peptides check <ext-link ext-link-type="uri" xlink:href="http://aps.unmc.edu/AP/database/antiC.php">http://aps.unmc.edu/AP/database/antiC.php</ext-link>.</p>
        </fn>
      </table-wrap-foot>
      <table-wrap-foot>
        <fn id="tblfn0010">
          <label>b</label>
          <p>Dolavaline (Dov), dolaisoleuine (Dil), dola-proine (Dap), dolaphenine (Doe).</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap id="tbl0010" position="float">
      <label>Table 2</label>
      <caption>
        <p><italic>In vivo</italic> studies of anticancer peptides and proposed mode of action.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="left">Peptide<xref rid="tblfn0015" ref-type="table-fn">a</xref></th>
            <th align="left">Mode of action</th>
            <th align="left">Type of tumor</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td colspan="3" align="left">α-Helical</td>
          </tr>
          <tr>
            <td align="left">Magainin and analogues</td>
            <td align="left">Lytic</td>
            <td align="left">Murine ascites tumors (<xref rid="bib0035" ref-type="bibr">Baker et al., 1993</xref>); melanoma xenograft in nude mice (<xref rid="bib0755" ref-type="bibr">Soballe et al., 1995</xref>)</td>
          </tr>
          <tr>
            <td align="left">Melittin/avidin-conjugate</td>
            <td align="left">Lytic</td>
            <td align="left">Melanoma in mice (<xref rid="bib0290" ref-type="bibr">Holle et al., 2003</xref>)</td>
          </tr>
          <tr>
            <td align="left">Polybia-MPI/MPI-1</td>
            <td align="left">Necrosis</td>
            <td align="left">Sarcoma xenograft tumors in mice (<xref rid="bib0920" ref-type="bibr">Zhang et al., 2010</xref>)</td>
          </tr>
          <tr>
            <td colspan="3" align="left">  </td>
          </tr>
          <tr>
            <td colspan="3" align="left">β-sheet</td>
          </tr>
          <tr>
            <td align="left">Human α-defensins</td>
            <td align="left">Apoptosis</td>
            <td align="left">Human lung adenocarcinoma xenograft in nude mice (<xref rid="bib0890" ref-type="bibr">Xu et al., 2008</xref>)</td>
          </tr>
          <tr>
            <td align="left">Gomesin</td>
            <td align="left">Necrosis</td>
            <td align="left">Murine melanoma (<xref rid="bib0660" ref-type="bibr">Rodrigues et al., 2008</xref>)</td>
          </tr>
          <tr>
            <td align="left">Lactoferricin B</td>
            <td align="left">Necrosis/Apoptosis</td>
            <td align="left">Fibrosarcoma, melanoma, colon carcinoma (<xref rid="bib0200" ref-type="bibr">Eliassen et al., 2002</xref>); Xenografting of SH-SY-5Y cells in nude rats (<xref rid="bib0195" ref-type="bibr">Eliassen et al., 2006</xref>); inhibition of metastasis of melanoma and lymphoma in mice (<xref rid="bib0905" ref-type="bibr">Yoo et al., 1997</xref>)</td>
          </tr>
          <tr>
            <td align="left">RGD-tachyplesin</td>
            <td align="left">Apoptosis</td>
            <td align="left">Melanoma mice (<xref rid="bib0130" ref-type="bibr">Chen et al., 2001</xref>)</td>
          </tr>
          <tr>
            <td colspan="3" align="left">  </td>
          </tr>
          <tr>
            <td colspan="3" align="left">Others</td>
          </tr>
          <tr>
            <td align="left">Dolastatin 10</td>
            <td align="left">Anti-proliferative</td>
            <td align="left">Indolent lymphoma, Waldenstrom's macroglobulinemia and chronic lymphocytic leukemia (<xref rid="bib0745" ref-type="bibr">Simmons et al., 2005</xref>)</td>
          </tr>
          <tr>
            <td colspan="3" align="left">  </td>
          </tr>
          <tr>
            <td colspan="3" align="left">Synthetic</td>
          </tr>
          <tr>
            <td align="left">[<sc>d</sc>]-K<sub>6</sub>L<sub>9</sub></td>
            <td align="left">Necrosis</td>
            <td align="left">Breast cancer in SCID/NCr mice (<xref rid="bib0565" ref-type="bibr">Papo et al., 2006</xref>)</td>
          </tr>
          <tr>
            <td align="left">[<sc>d</sc>]-H<sub>6</sub>L<sub>9</sub></td>
            <td align="left">Lytic</td>
            <td align="left">22RV1 prostate cancer in mice (<xref rid="bib0430" ref-type="bibr">Makovitzki et al., 2009</xref>)</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn id="tblfn0015">
          <label>a</label>
          <p>Source and amino acid composition of peptides are listed in <xref rid="tbl0005" ref-type="table">Table 1</xref>.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
  </floats-group>
</article>